var title_f18_18_18720="Endosc fundic gland polyp A";
var content_f18_18_18720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric fundic gland polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of the body of the stomach looking toward the antrum and pylorus showing numerous polypoid lesions, which on biopsy were proven to be fundic gland polyps.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Akira Horiuchi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18720=[""].join("\n");
var outline_f18_18_18720=null;
var title_f18_18_18721="Scabies";
var content_f18_18_18721=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Scabies (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/18/18721/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18721/contributors\" id=\"au5343\">",
"       Beth G Goldstein, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18721/contributors\" id=\"au5345\">",
"       Adam O Goldstein, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/18/18721/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18721/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18721/contributors\" id=\"se4893\">",
"       Moise L Levy, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/18/18721/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18721/contributors\" id=\"de2840\">",
"       Abena O Ofori, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?18/18/18721?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SCABIES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Scabies is an infestation of the skin by a mite called Sarcoptes scabiei. It causes intense itching and can be spread from one person to another through close skin-to-skin contact. Fortunately, effective treatments for scabies are available.",
"    </p>",
"    <p>",
"     Scabies became more common in North America and Europe during the 1960s, and peaked around 1980. It has declined somewhat since then, but scabies remains a common problem, affecting as many as 300 million people worldwide [",
"     <a class=\"abstract\" href=\"UTD.htm?18/18/18721/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SCABIES APPEARANCE",
"     </span>",
"    </p>",
"    <p>",
"     The scabies mite has eight legs, is whitish-brown in color, and is nearly invisible to the naked eye. The symptoms of scabies are caused by the female mites, which tunnels into the skin after being fertilized. The female lays eggs under the skin and continues to tunnel until she dies, usually after a month or two. When the eggs hatch, new mites travel back to the surface of the skin, then mate and repeat the cycle of tunneling and laying more eggs. A person who is infected with scabies typically has around 12 mites at any given time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HOW IS SCABIES SPREAD?",
"     </span>",
"    </p>",
"    <p>",
"     Scabies is usually passed from one person to another through close skin-to-skin contact. It is common for infected parents to pass scabies to their child (particularly an infant) or vice versa as a result of close contact. However, it is unusual for school children to pass scabies to each other. It takes about three to four weeks for signs or symptoms of a first scabies infection to develop after infection. People who have been infected with scabies previously may develop symptoms within a few days after another exposure.",
"    </p>",
"    <p>",
"     The most common mode of transmission between young adults is sexual contact, although the infection can be passed without sexual activity.",
"    </p>",
"    <p>",
"     The mites that cause scabies only survive for 24 to 36 hours once they are no longer in contact with the skin; however, they may survive longer in colder conditions. As a result, scabies tends to be more common in the winter than in the summer.",
"    </p>",
"    <p>",
"     Although uncommon, it is possible for a person to get scabies by wearing or handling heavily infected clothing, or sleeping in an unchanged bed recently occupied by an infected individual. This is more likely with a severe form of the condition called crusted scabies (see",
"     <a class=\"local\" href=\"#H6\">",
"      'Crusted scabies'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Animals can also become infected with scabies (a condition called mange), although animals are affected by a different type of mite. This mite can tunnel under the skin and cause itching in humans, but it does not reproduce and does not require treatment because symptoms resolve when the mite dies (usually within a few days). People who suspect that their pet has mange should have the animal evaluated by a veterinarian. Getting the proper treatment for the pet will prevent new mites from infecting the human.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      SCABIES SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Typical scabies",
"     </span>",
"     &nbsp;&mdash;&nbsp;The primary symptom of scabies is widespread itching, which may be severe and is usually worse at night.",
"    </p>",
"    <p>",
"     Scabies also causes visible lesions (reddish bumps or blisters) on the skin; however, these are often very small and can be difficult to see (",
"     <a class=\"graphic graphic_picture graphicRef54705 \" href=\"UTD.htm?3/58/4000\">",
"      picture 1",
"     </a>",
"     ). These bumps or blisters are often more noticeable in children, especially if they scratch frequently.",
"    </p>",
"    <p>",
"     A person may also notice a \"burrow\" or tunnel sign, a thin, visible line in the skin that extends from 2 to 15 millimeters (0.08 to 0.6 inches). Although not everyone with scabies has visible burrows, the presence of such marks strongly suggests scabies (see",
"     <a class=\"local\" href=\"#H7\">",
"      'Do I have scabies?'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     The following parts of the body are more likely than others to be affected by scabies (",
"     <a class=\"graphic graphic_figure graphicRef79896 \" href=\"UTD.htm?40/16/41218\">",
"      figure 1",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The fingers and webbing between the fingers",
"      </li>",
"      <li>",
"       The skin folds around the wrists, elbows, and knees",
"      </li>",
"      <li>",
"       The armpits",
"      </li>",
"      <li>",
"       The area surrounding the nipples (particularly in women)",
"      </li>",
"      <li>",
"       The waist",
"      </li>",
"      <li>",
"       The male genitalia (penis and scrotum)",
"      </li>",
"      <li>",
"       The lower buttocks and upper thighs",
"      </li>",
"      <li>",
"       The sides and bottoms of the feet",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The back is usually not affected, nor is the head (except sometimes in infants or very young children).",
"    </p>",
"    <p>",
"     Scabies lesions can become more irritated and inflamed with scratching, which may lead to infection. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'Treating infection'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Crusted scabies",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with a weakened immune system (including those with HIV infection, lymphoma, or other conditions) may develop \"crusted scabies\", also called \"Norwegian scabies\". This condition may also affect elderly people or those with Down syndrome.",
"    </p>",
"    <p>",
"     Crusted scabies causes large, crusty red patches or bumps on the skin, which spread easily if untreated. The scalp, hands, and feet are often affected, although the patches can occur on any part of the body. The lesions of crusted scabies often contain large numbers of mites, although there may be little to no itching.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      DO I HAVE SCABIES?",
"     </span>",
"    </p>",
"    <p>",
"     Scabies is usually diagnosed based upon symptoms (widespread itching, presence of bumps) and history (eg, whether family members or sexual partners also have these signs). A healthcare provider may be able to confirm the diagnosis by scraping the top layers of skin at the site of a lesion and examining it under a microscope for mites or eggs; however, this is not usually necessary.",
"    </p>",
"    <p>",
"     Anyone who has symptoms of scabies should see their healthcare provider to be evaluated and confirm the diagnosis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      SCABIES MANAGEMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Getting rid of mites",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most commonly used treatment for scabies is a topical (cream) medication such as permethrin (Elimite&reg;, Acticin&reg;). People with crusted scabies are usually treated with permethrin and an anti-parasitic pill",
"     <span class=\"nowrap\">",
"      (ivermectin/Stromectol&reg;).",
"     </span>",
"     Permethrin 5 percent cream (Acticin&reg;, Elimite&reg;) is usually the preferred treatment for pregnant women and infants.",
"    </p>",
"    <p>",
"     In order for any treatment to be successful, it must be used correctly. Creams or lotions must be applied carefully to cover all skin from the neck down, and rinsed off according to instructions. Talk to a healthcare provider to be sure you understand which treatment is recommended and how to properly use it.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Treat family members",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some cases, household members and close contacts of a person with symptoms need treatment for scabies, even if there are no symptoms, to avoid a repeating cycle of infection. A healthcare provider can help to decide if this is necessary, depending upon the individual situation.",
"    </p>",
"    <p>",
"     Although scabies is less frequently spread by touching the clothing or bedsheets of an infected person, it is still a good idea to wash or isolate any clothing, bedding, towels, pajamas, underwear, or stuffed animals that the person has touched within three days before treatment. It is not usually necessary to wash other items. Reasonable options for eliminating mites from these items include placing them in plastic bags for at least three days, machine washing and then ironing or drying in an electric dryer on the hot setting, or dry cleaning.",
"    </p>",
"    <p>",
"     Crusted scabies is more likely to be spread through shared clothing or objects than typical scabies (see",
"     <a class=\"local\" href=\"#H6\">",
"      'Crusted scabies'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Relieving itching",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antihistamines may help to control itching. Non-sedating antihistamines, such as loratadine (Claritin&reg;) or cetirizine (Zyrtec&reg;), are generally recommended during the day while sedating antihistamines (eg,",
"     <span class=\"nowrap\">",
"      diphenhydramine/Benadryl&reg;)",
"     </span>",
"     can help to control itching and improve sleep at night.",
"    </p>",
"    <p>",
"     Itching may persist for several weeks after mites are eliminated; a steroid cream or a course of oral glucocorticoids may be recommended if itching is severe. If symptoms persist or become worse, the person may have become re-infected.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Treating infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;The skin usually heals without difficulty after mites are treated. Keeping the skin clean and dry and avoiding scratching can help to prevent infection. However, if signs of a skin infection develop (eg, redness, swelling, pus, pain), oral antibiotics are generally recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Return to work/school",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children can usually return to school after one treatment for scabies. Classmates and teachers do not usually need to be treated unless there are signs or symptoms of scabies infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13673502\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13673509\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/19/1330?source=see_link\">",
"      Patient information: Scabies (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13673533\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H866771069\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37318?source=see_link\">",
"      Approach to the patient with a scalp eruption",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28423?source=see_link\">",
"      Approach to the patient with pustular skin lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link\">",
"      Scabies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/scabies.html\">",
"      www.nlm.nih.gov/medlineplus/scabies.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/scabies/\">",
"      www.cdc.gov/scabies/",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Nemours Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/parent/infections/skin/scabies.html\">",
"      file://kidshealth.org/parent/infections/skin/scabies.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     UpToDate wishes to acknowledge Kelly Crowley for her contributions to this topic.",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?18/18/18721/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?18/18/18721?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18721/abstract/1\">",
"      Chosidow O. Clinical practices. Scabies. N Engl J Med 2006; 354:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18721/abstract/2\">",
"      Heukelbach J, Feldmeier H. Scabies. Lancet 2006; 367:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18721/abstract/3\">",
"      Johnston G, Sladden M. Scabies: diagnosis and treatment. BMJ 2005; 331:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18721/abstract/4\">",
"      Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev 2007; :CD000320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18721/abstract/5\">",
"      Casey C, Vellozzi C, Mootrey GT, et al. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18721/abstract/6\">",
"      Karthikeyan K. Treatment of scabies: newer perspectives. Postgrad Med J 2005; 81:7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f18_18_18721=[""].join("\n");
var outline_f18_18_18721=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SCABIES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SCABIES APPEARANCE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HOW IS SCABIES SPREAD?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           SCABIES SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           DO I HAVE SCABIES?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           SCABIES MANAGEMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/16/41218\" title=\"figure 1\">",
"           Scabies distribution PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/58/4000\" title=\"picture 1\">",
"           Interdigital scabies PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f18_18_18722="Pulm AVM CXR II";
var content_f18_18_18722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows multiple small nodular arteriovenous malformations with distorted peripheral vascularity of the lungs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18722=[""].join("\n");
var outline_f18_18_18722=null;
var title_f18_18_18723="D-Lactic acidosis";
var content_f18_18_18723=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   D-Lactic acidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18723/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18723/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18723/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18723/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18723/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18723/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/18/18723/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A unique form of lactic acidosis can occur in patients with jejunoileal bypass or, less commonly, small bowel resection or other causes of the short bowel syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=see_link\">",
"     \"Management of the short bowel syndrome in adults\"",
"    </a>",
"    .) In these settings, glucose, starch, and other carbohydrates can be metabolized in the colon to D-lactic acid, which is then absorbed into the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The ensuing acidemia tends to persist, since D-lactate is not metabolized by L-lactate dehydrogenase, the enzyme that catalyzes the conversion of the physiologically occurring L-lactate into pyruvate. Thus, D-lactate is slowly metabolized in humans.",
"   </p>",
"   <p>",
"    Two factors tend to contribute to the overproduction of D-lactic acid in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is overgrowth of gram-positive anaerobes, such as Lactobacilli, which are most able to produce D-lactate.",
"     </li>",
"     <li>",
"      There is usually relatively little glucose and starch delivered to the colon because of extensive small intestinal absorption. However, delivery of these substrates is markedly enhanced when the small bowel is bypassed, removed, or diseased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A potential concern is whether patients undergoing continuous peritoneal dialysis are at risk for D-lactic acidosis, since the dialysate solution contains a racemic mixture of L- and D-lactate. Several small studies suggest that D-lactate does not accumulate in peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]; it remains possible, however, that occasional patients might be at risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with short bowel syndrome frequently demonstrate chronically elevated serum concentrations of D-lactate that are not sufficient to induce symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/8\">",
"     8",
"    </a>",
"    ]. In some patients, however, carbohydrate loading leads to severe and symptomatic D-lactic acidosis. These patients typically present with episodic metabolic acidosis (usually occurring after high carbohydrate meals) and characteristic neurologic abnormalities including confusion, cerebellar ataxia, slurred speech, and loss of memory (",
"    <a class=\"graphic graphic_table graphicRef73367 \" href=\"UTD.htm?9/34/9772\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/1-3,9\">",
"     1-3,9",
"    </a>",
"    ]. In a review of 29 reported cases, all patients exhibited some degree of altered mental status [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/9\">",
"     9",
"    </a>",
"    ]. They may complain of feeling drunk or appear to be drunk in the absence of ethanol intake.",
"   </p>",
"   <p>",
"    It is not clear if these symptoms are due to D-lactate itself or to some other toxin produced in the colon and then absorbed in parallel with D-lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Evidence in support of the latter hypothesis includes the lack of correlation between plasma or cerebrospinal concentrations of D-lactate and symptoms, and the inability to reproduce neurologic symptoms in normal subjects administered D-lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of D-lactic acidosis should be strongly considered in the patient presenting with an increased serum anion gap, normal serum concentrations of lactate, negative ketones, and one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Short bowel or other malabsorption syndrome",
"     </li>",
"     <li>",
"      Acidosis that is preceded by food intake and resolves with its discontinuation",
"     </li>",
"     <li>",
"      Characteristic neurologic symptoms and signs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Confirmation of the diagnosis requires a special enzymatic assay that uses D-lactate dehydrogenase and measures the generation of NADH as lactate is converted to pyruvate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In contrast, the standard assay for lactate uses L-lactate dehydrogenase, which will",
"    <strong>",
"     not",
"    </strong>",
"    detect D-lactate.",
"   </p>",
"   <p>",
"    An additional potential source of confusion is that the increase in anion gap may be normal or less than expected from the degree of fall in the plasma bicarbonate concentration. This effect is related to the stereospecificity of the sodium-L-lactate cotransporter in the luminal membrane of the proximal tubule. As a result, filtered D-lactate is not well reabsorbed and is rapidly excreted in the urine, thereby lowering the anion gap toward normal if the lactate is excreted as the sodium or potassium salt.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/21/8530?source=see_link\">",
"     Sodium lactate",
"    </a>",
"    loss in the stool (with the hydrogen ion being absorbed) can also contribute to this process [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urine anion gap (Na + K &ndash; Cl) is usually negative in patients with metabolic acidosis because urinary ammonium (NH4+) excretion is increased (as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=see_link\">",
"     ammonium chloride",
"    </a>",
"    ), but ammonium is not measured as a urine cation. Thus, in patients with a normal plasma anion gap acidosis, a negative urine anion gap is expected and a positive value suggests impaired urinary acidification as occurs in renal failure or renal tubular acidosis. D-lactate is an unmeasured anion and will therefore counteract the effect of the unmeasured cation ammonium. As a result, the urine anion gap may be positive, erroneously suggesting renal tubular acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/10\">",
"     10",
"    </a>",
"    ]. In this setting, ammonium excretion is best estimated by measurement of the urine osmolal gap. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11558?source=see_link\">",
"     \"Urine anion and osmolal gaps in metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of D-lactic acidosis consists of acute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    administration to correct the acidemia and oral antimicrobial agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) to decrease the number of D-lactate producing organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. A low carbohydrate diet (or the use of starch polymers rather than simple sugars) also is helpful, by diminishing carbohydrate delivery to the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. It is important to appreciate, however, that antimicrobials can occasionally precipitate D-lactic acidosis in susceptible subjects by causing the overgrowth of Lactobacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18723/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16949900\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      D-Lactic acidosis can occur in patients with jejunoileal bypass or, less commonly, small bowel resection or other causes of the short bowel syndrome. Overgrowth of gram positive anaerobes and excessive delivery of glucose and starch to the colon contribute to excessive production of D-lactic acid. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with D-lactic acidosis typically present with episodic metabolic acidosis after high carbohydrate meals associated with confusion, cerebellar ataxia, slurred speech, and loss of memory. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis should be considered in the setting of increased serum anion gap, normal serum L-lactate concentrations, normal plasma ketoacid levels, negative urine ketones, and a characteristic",
"      <span class=\"nowrap\">",
"       history/signs/symptoms.",
"      </span>",
"      Confirmation of the diagnosis requires a special enzymatic assay because the standard assay for lactate uses L-lactate dehydrogenase, which will",
"      <strong>",
"       not",
"      </strong>",
"      detect D-lactate. The plasma anion gap may not be increased in proportion to the decrease in serum bicarbonate because D-lactate is not well reabsorbed by the renal tubules and is more readily excreted in the urine, thereby lowering the anion gap. Measurement of the urine anion gap may be misleading. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy of D-lactic acidosis consists of acute",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      administration, oral antimicrobial agents (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ) to decrease the number of D-lactic acid producing organisms, and a low carbohydrate diet. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/1\">",
"      Stolberg L, Rolfe R, Gitlin N, et al. d-Lactic acidosis due to abnormal gut flora: diagnosis and treatment of two cases. N Engl J Med 1982; 306:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/2\">",
"      Oh MS, Uribarri J, Carroll HJ. Electrolyte case vignette: a case of unusual organic acidosis. Am J Kidney Dis 1988; 11:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/3\">",
"      Halperin ML, Kamel KS. D-lactic acidosis: turning sugar into acids in the gastrointestinal tract. Kidney Int 1996; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/4\">",
"      Bongaerts G, Bakkeren J, Severijnen R, et al. Lactobacilli and acidosis in children with short small bowel. J Pediatr Gastroenterol Nutr 2000; 30:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/5\">",
"      Uchida H, Yamamoto H, Kisaki Y, et al. D-lactic acidosis in short-bowel syndrome managed with antibiotics and probiotics. J Pediatr Surg 2004; 39:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/6\">",
"      Nolph KD, Twardowski ZJ, Khanna R, et al. Tidal peritoneal dialysis with racemic or L-lactate solutions. Perit Dial Int 1990; 10:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/7\">",
"      Fine A. Metabolism of D-lactate in the dog and in man. Perit Dial Int 1989; 9:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/8\">",
"      Bongaerts G, Tolboom J, Naber T, et al. D-lactic acidemia and aciduria in pediatric and adult patients with short bowel syndrome. Clin Chem 1995; 41:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/9\">",
"      Uribarri J, Oh MS, Carroll HJ. D-lactic acidosis. A review of clinical presentation, biochemical features, and pathophysiologic mechanisms. Medicine (Baltimore) 1998; 77:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/10\">",
"      Narula RK, El Shafei A, Ramaiah D, Schmitz PG. D-lactic acidosis 23 years after jejuno-ileal bypass. Am J Kidney Dis 2000; 36:E9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/11\">",
"      Mayne AJ, Handy DJ, Preece MA, et al. Dietary management of D-lactic acidosis in short bowel syndrome. Arch Dis Child 1990; 65:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18723/abstract/12\">",
"      Coronado BE, Opal SM, Yoburn DC. Antibiotic-induced D-lactic acidosis. Ann Intern Med 1995; 122:839.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2303 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18723=[""].join("\n");
var outline_f18_18_18723=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16949900\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16949900\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2303\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2303|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/34/9772\" title=\"table 1\">",
"      Neurologic sx D lactic acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=related_link\">",
"      Management of the short bowel syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=related_link\">",
"      The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11558?source=related_link\">",
"      Urine anion and osmolal gaps in metabolic acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_18_18724="Protamine sulfate: Pediatric drug information";
var content_f18_18_18724=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Protamine sulfate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=see_link\">",
"    see \"Protamine sulfate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/62/25571?source=see_link\">",
"    see \"Protamine sulfate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7255805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Heparin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Limited data in neonates. Doses are extrapolated from adult information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Protamine dosage is determined by the most recent dosage of heparin or low molecular weight heparin (LMWH); 1 mg of protamine sulfate neutralizes 90 USP units of heparin (lung), 115 USP units of heparin (intestinal), and 1 mg of enoxaparin; maximum dose: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Heparin overdosage: Since blood heparin concentrations decrease rapidly",
"     <b>",
"      after",
"     </b>",
"     heparin administration, adjust the protamine dosage depending upon the duration of time since heparin administration as follows (see table):",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"211\">",
"     </col>",
"     <col align=\"center\" width=\"248\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Time Since Last Heparin Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (min)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose of Protamine (mg) to Neutralize",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         100 units of Heparin",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-0.75",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.375-0.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25-0.375",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LMWH overdosage: If most recent LMWH dose has been administered within the last 4 hours, use 1 mg protamine per 1 mg (100 units) LMWH; a second dose of 0.5 mg protamine per 1 mg (100 units) LMWH may be given if APTT remains prolonged 2-4 hours after the first dose; one report described dividing the total protamine dose and administering to a target Anti-Xa level to avoid potential protamine toxicity (Wiernikowski, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=see_link\">",
"      see \"Protamine sulfate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infants, Children and Adults: Protamine dosage is determined by the most recent dosage of heparin or low molecular weight heparin (LMWH); 1 mg of protamine neutralizes 90 USP units of heparin (lung), 115 USP units of heparin (intestinal), and 1 mg (100 units) LMWH; maximum dose: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Heparin overdosage: Since blood heparin concentrations decrease rapidly",
"     <b>",
"      after",
"     </b>",
"     heparin administration, adjust the protamine dosage depending upon the duration of time since heparin administration as follows (see table):",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"211\">",
"     </col>",
"     <col align=\"center\" width=\"248\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Time Since Last Heparin Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (min)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose of Protamine (mg) to Neutralize",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         100 units of Heparin",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-0.75",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.375-0.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25-0.375",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If heparin is administered by deep SubQ injection, use 1-1.5 mg protamine per 100 units heparin; this may be done by administering a portion of the dose (eg, 25-50 mg) slowly I.V. followed by the remaining portion as a continuous infusion over 8-16 hours (the expected absorption time of the SubQ heparin dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     LMWH overdosage: If most recent LMWH dose has been administered within the last 4 hours, use 1 mg protamine per 1 mg (100 units) LMWH; a second dose of 0.5 mg protamine per 1 mg (100 units) LMWH may be given if APTT remains prolonged 2-4 hours after the first dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [preservative free]: 10 mg/mL (5 mL, 25 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Inject without further dilution over 10 minutes not to exceed 5 mg/minute; maximum of 50 mg in any 10-minute period",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F215173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Iohexol 64.7%, iopamidol 61%, iothalamate meglumine 60%.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide, ioxaglate meglumine 39.3%, ioxaglate sodium 19.6%.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refrigerate; stable for at least 2 weeks at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of heparin overdosage; neutralize heparin during surgery or dialysis procedures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F215175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Protamine may be confused with ProAmatine, Protonix&reg;, Protopam&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F215172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, flushing, hypotension, sudden fall in blood pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Lassitude",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pulmonary hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to protamine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients allergic to fish, with prior history of vasectomy, and patients receiving protamine-containing insulin or previous protamine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anaphylactic reactions may occur; hypotension and other cardiovascular events (including cardiovascular collapse, noncardiogenic pulmonary edema, pulmonary vasoconstriction, and pulmonary hypertension) may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk factors include rapid administration, high doses or overdose, repeated doses, previous protamine administration (including protamine-containing drugs such as NPH insulin), fish allergy, vasectomy, severe left ventricular dysfunction, and abnormal preoperative pulmonary hemodynamics. Heparin rebound associated with anticoagulation and bleeding has been reported to occur occasionally; symptoms typically occur 8-9 hours after protamine administration, but may occur as long as 18 hours later",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F215121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13801118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2004). Protamine sulfate may be used during delivery to reduce the risk of bleeding following maternal use of heparin or low molecular weight heparin (LMWH) (Bates,  2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Coagulation tests, APTT or ACT, cardiac monitor, and blood pressure monitor required during administration",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combines with strongly acidic heparin to form a stable complex (salt) neutralizing the anticoagulant activity of both drugs",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Heparin neutralization occurs within 5 minutes following I.V. injection",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination: Unknown",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Moganasundram S, Hunt BJ, Sykes K, et al, \"The Relationship Among Thromboelastography, Hemostatic Variables, and Bleeding After Cardiopulmonary Bypass Surgery in Children,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2010, 110(4):995-1002.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/18/18724/abstract-text/20142345/pubmed\" id=\"20142345\" target=\"_blank\">",
"        20142345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chalmers E, Chan A, et al, \"Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):887-968.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/18/18724/abstract-text/18574281/pubmed\" id=\"18574281\" target=\"_blank\">",
"        18574281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiernikowski JT, Chan A, and Lo G, \"Reversal of Anti-Thrombin Activity Using Protamine Sulfate. Experience in a Neonate With a 10-fold Overdose of Enoxaparin,\"",
"      <i>",
"       Thromb Res",
"      </i>",
"      , 2007, 120(2):303-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/18/18724/abstract-text/17079003/pubmed\" id=\"17079003\" target=\"_blank\">",
"        17079003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12746 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18724=[""].join("\n");
var outline_f18_18_18724=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7255805\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061565\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675557\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061560\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215125\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215111\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061568\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215173\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061562\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061567\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215175\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215172\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061572\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061559\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061558\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299956\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222615\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215121\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13801118\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061564\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061557\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061570\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061571\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12746\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12746|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=related_link\">",
"      Protamine sulfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/62/25571?source=related_link\">",
"      Protamine sulfate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_18_18725="Nadolol and bendroflumethiazide: Patient drug information";
var content_f18_18_18725=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nadolol and bendroflumethiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/8/36998?source=see_link\">",
"     see \"Nadolol and bendroflumethiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Corzide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nadolol, bendroflumethiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, kidney disease, very weak heart, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablet with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11224 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18725=[""].join("\n");
var outline_f18_18_18725=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198966\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020666\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020668\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020667\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020672\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020673\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020675\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020670\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020671\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020676\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020677\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/8/36998?source=related_link\">",
"      Nadolol and bendroflumethiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_18_18726="Thyroid disorders and connective tissue disease";
var content_f18_18_18726=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thyroid disorders and connective tissue disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18726/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18726/contributors\">",
"     Lesley D Hordon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18726/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18726/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18726/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18726/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/18/18726/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of thyroid disease, particularly chronic autoimmune thyroiditis (Hashimoto's thyroiditis), may be increased in patients with connective tissue diseases. However, it is important to remember that chronic autoimmune thyroiditis, manifested by positive tests for antithyroid antibodies, is common in the general population (occurring in 10 to 20 percent of women and 1 to 2 percent of men) and hypothyroidism (subclinical or overt) is only slightly less common [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, both hypothyroidism and connective tissue diseases often cause muscle and joint aches, pains, and stiffness, and common treatments for connective tissue diseases and the illnesses themselves may affect thyroid function or thyroid function tests.",
"   </p>",
"   <p>",
"    Given the high frequency of chronic autoimmune thyroiditis and hypothyroidism in patients with no other problems, the literature describing the occurrence of thyroid disease in patients with a connective tissue disease should be viewed with considerable caution. Most of the studies were performed in specialty clinics, so the likelihood of selection bias is high. Diagnostic criteria for thyroid disease may also vary between studies. Furthermore, there is only limited evidence that the concurrence in the same patient of thyroid disease and connective tissue disease alters the clinical manifestations or natural history of either disorder. Examples are scleroderma, in which fibrosis of the thyroid gland can occur and cause hypothyroidism independently of chronic autoimmune thyroiditis, and complete congenital heart block in children of hypothyroid anti-Ro positive mothers.",
"   </p>",
"   <p>",
"    Another part of this relationship is that the drugs used to treat connective tissue diseases and the underlying illness can affect thyroid function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids inhibit thyrotropin (TSH) secretion and slightly reduce serum thyroid hormone concentrations.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      and some nonsteroidal antiinflammatory drugs lower serum total thyroid hormone concentrations by interfering with thyroid hormone binding to its carrier proteins; serum free thyroid hormone concentrations do not change.",
"     </li>",
"     <li>",
"      Any major illness, including connective tissue diseases, can lower serum thyroid hormone and TSH concentrations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42632?source=see_link\">",
"     \"Drug interactions with thyroid hormones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THYROID DISORDERS IN CONNECTIVE TISSUE DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The associations of thyroid and connective tissue diseases and data concerning the presence of antinuclear antibodies in patients with thyroid disease are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Polymyalgia rheumatica/giant cell arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data concerning the prevalence of hypothyroidism in patients with polymyalgia rheumatica and giant cell arteritis are conflicting. Some reports have described an increased prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], while others have questioned the association [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest prospective study evaluated 367 patients with polymyalgia rheumatica or giant cell arteritis: hypothyroidism was found in 4.9 percent, as compared with none of 84 normal subjects and 1.6 percent of elderly normal subjects from other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the frequency of hypothyroidism in the control groups in this study was unusually low. As an example, in a smaller study of 39 patients with giant cell arteritis, biochemical thyroid dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thyroid antibodies were found in 26 percent, as compared with 31 percent of the control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/4\">",
"     4",
"    </a>",
"    ], and in a retrospective study none of 77 patients with polymyalgia rheumatica or giant cell arteritis had hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, polymyalgia",
"    <span class=\"nowrap\">",
"     rheumatica/giant",
"    </span>",
"    cell arteritis may be more common in patients with autoimmune thyroid disease. One series found a prevalence of 2.8 percent in 250 patients with autoimmune thyroid disease, rising to 9.3 percent in women over the age of 60 years; in comparison, there were no cases of polymyalgia",
"    <span class=\"nowrap\">",
"     rheumatica/giant",
"    </span>",
"    cell arteritis among 150 control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fibromyalgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A blunted response of serum TSH to thyrotropin-releasing hormone (TRH) has been described in a small number of patients with fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The importance of this finding is unclear. It could be due to an increase in cortisol secretion, due either to the fibromyalgia itself or to the depression that often accompanies it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=see_link\">",
"     \"Pathogenesis of fibromyalgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another small study showed an increased prevalence of antithyroid antibodies in patients with fibromyalgia compared to controls and similar to the prevalence seen in patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/9\">",
"     9",
"    </a>",
"    ]. Sicca symptoms seemed more frequent in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 to 20 percent of patients with systemic lupus erythematosus (SLE) have antithyroid antibodies (most often measured as antithyroid peroxidase [microsomal] antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]), a slightly higher percentage than is found in normal subjects of the same age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/10\">",
"     10",
"    </a>",
"    ]. The antibody titers may fluctuate and clinical thyroid disease is associated with the persistent presence of these antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/12\">",
"     12",
"    </a>",
"    ]. In terms of thyroid disease, the following observations have been noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of overt thyroid disease appears to be between 3 and 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/10,12-17\">",
"       10,12-17",
"      </a>",
"      ], with subclinical or overt hypothyroidism being more common than hyperthyroidism in most studies. In a study of 153 SLE patients screened for thyroid disease, there was a significant increase in the prevalence of hypothyroidism (19 percent), hyperthyroidism (9 percent), and thyroid antibodies (33 percent) in comparison with controls (2 percent, 1 percent, and 13 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/17\">",
"       17",
"      </a>",
"      ]. Papillary thyroid cancer was found in five of the SLE patients compared with 1 of the 459 controls, with a relative risk of 14.5. The presence of thyroid cancer did not appear to be related to the treatment of SLE, but thyroid autoimmunity may be a predisposing condition for thyroid cancer in this group of patients.",
"     </li>",
"     <li>",
"      In a study of 3286 Caucasian people with Graves&rsquo; disease (2791 cases) or Hashimoto&rsquo;s thyroiditis (495 cases), there was a significantly increased relative risk of SLE in both diseases, with the relative risk in women being over 10-fold [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/18\">",
"       18",
"      </a>",
"      ]. There was also an increased risk of SLE noted in the men with Graves&rsquo; disease.",
"     </li>",
"     <li>",
"      Part of the association between SLE and thyroid disease may be due to genetic factors. In a study of 378 multiplex SLE families, 35 also had autoimmune thyroid disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/19\">",
"       19",
"      </a>",
"      ]. A genetic linkage effect in the region of D5S1462 on the chromosome 5q14.3-15 was demonstrated between these two related autoimmune conditions. In a study of families with more than one member affected by SLE, family members with SLE and secondary Sj&ouml;gren's syndrome had a higher prevalence of autoimmune thyroid disease than SLE family members without secondary Sj&ouml;gren's syndrome (30 versus 13 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increased risk of preterm delivery has been noted in pregnant women with SLE and thyroid disease. In a retrospective study of 63 pregnant women with SLE, 37.9 percent of the cohort had thyroid disease diagnosed before, during, or immediately after pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/21\">",
"       21",
"      </a>",
"      ]. Preterm delivery occurred in 67 percent of the women who had thyroid disease, compared with 18 percent of the women with SLE who remained free of thyroid disease. Thyroid antibodies did not predict preterm delivery in this group of women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sj&ouml;gren's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the prevalence of thyroid disease in patients with Sj&ouml;gren's syndrome vary widely, ranging from 10 to 70 percent. Some of the variance may be accounted for by different criteria for thyroid disease (eg, abnormalities in thyroid structure, hormonal function, or presence of autoantibodies). Observations of a higher prevalence of thyroid disease in this population may also represent confounding factors as demographic features that favor Sj&ouml;gren's syndrome also increase the risk of thyroid disease (eg, female sex and advancing age). However, a study of 114 patients with primary Sj&ouml;gren's syndrome showed 14 percent to have hypothyroidism, while thyrotoxicosis had occurred in 1.8 percent of the same cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"    </a>",
"    .) Autoimmune disease, including autoimmune thyroid disease, has been shown to cluster in first degree relatives of patients with Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, symptoms of Sj&ouml;gren's syndrome may occur with increased frequency in patients with autoimmune thyroiditis. As an example, 32 percent of 19 patients with chronic autoimmune thyroiditis had keratoconjunctivitis sicca and xerostomia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective study of 91 patients with rheumatoid arthritis found that 30 percent had some evidence of clinical or subclinical thyroid disease, as compared with 11 percent of patients with osteoarthritis or fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/25\">",
"     25",
"    </a>",
"    ]. The frequency of antithyroid antibodies also may be increased in patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Psoriatic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithyroid antibodies and subclinical hypothyroidism were found more frequently in women with psoriatic arthritis than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/27\">",
"     27",
"    </a>",
"    ]. Men with psoriatic arthritis had an increased prevalence of antithyroid antibodies alone. Subclinical hypothyroidism occurred in 25 percent of women with psoriatic arthritis compared to 8 percent of controls and 12 percent of women with rheumatoid arthritis and appeared to be associated with polyarticular involvement and longer disease duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mixed connective tissue disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the frequency of thyroid disease in mixed connective tissue disease. One report of 22 patients with this disorder found antithyroid antibodies in 23 percent and hypothyroidism in 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/28\">",
"     28",
"    </a>",
"    ]. A larger study of 159 patients found a similar prevalence of antithyroid antibodies, present in 21 percent of patients, all of whom required thyroxine treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Scleroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism occurs more frequently in women with scleroderma than in control populations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. As mentioned above, fibrosis of the thyroid gland can directly cause hypothyroidism in patients with scleroderma and appears to be responsible for most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. This was illustrated in a study of 202 patients with scleroderma compared with population-based controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/31\">",
"     31",
"    </a>",
"    ]. Clinical (4 versus 0.3 percent) and subclinical (17 versus 6 percent) hypothyroidism was more common in female scleroderma subjects than controls. Thyroid antiperoxidase antibodies were not significantly different between hypothyroid and non-hypothyroid scleroderma subjects.",
"   </p>",
"   <p>",
"    However, in a study of 138 patients with scleroderma, antithyroid peroxidase antibodies were increased in patients with limited scleroderma, whereas the levels of these antibodies in patients with diffuse scleroderma were similar to those in healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/34\">",
"     34",
"    </a>",
"    ]. These findings support the hypothesis that hypothyroidism in limited scleroderma may reflect thyroid autoimmunity, while fibrosis may be the mechanism of hypothyroidism in diffuse scleroderma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antinuclear antibodies in patients with thyroid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antinuclear antibodies have been detected in the serum of patients with both Graves' disease and chronic autoimmune thyroiditis in some but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. In the most comprehensive study including 22 patients with Graves' hyperthyroidism and 28 with chronic autoimmune thyroiditis, 13 (26 percent) had antinuclear antibodies and 17 (34 percent) had anti-single-stranded DNA antibodies (the percentages were about the same in each patient group) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/37\">",
"     37",
"    </a>",
"    ]. No patient had antibodies against double-stranded DNA, extractable nuclear antigens",
"    <span class=\"nowrap\">",
"     (anti-Ro/SSA,",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-La/SSB,",
"    </span>",
"    anti-Sm, and anti-RNP), mitochondria, or rheumatoid factor. There is no model of autoimmune thyroid disease in which anti-DNA or related antibodies are pathophysiologically important.",
"   </p>",
"   <p>",
"    Maternal anti-Ro antibodies are associated with complete congenital heart block in infants. A study showed that maternal hypothyroidism was more common in women with anti-Ro antibodies and was associated with an increased risk of a child with complete congenital heart block compared with anti-Ro positive women with normal thyroid function (56 percent compared with 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18726/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although thyroid disease is common in the general population, there appears to be an increased frequency of subclinical and, less frequently, overt hypothyroidism in association with many autoimmune rheumatic diseases. The frequency of hyperthyroidism in these patients is less common than hypothyroidism and appears to be similar or only slightly increased compared to that seen in the general population. It is reasonable to assess thyroid function tests in most patients on presentation and periodically thereafter. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Thyroid disorders in connective tissue diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is limited evidence that the concurrence in the same patient of thyroid disease and connective tissue disease alters the clinical manifestations or natural history of either disorder. In patients with scleroderma, fibrosis of the thyroid gland can occur and cause hypothyroidism independently of chronic autoimmune thyroiditis. In addition, an increased risk of preterm delivery has been noted in pregnant women with SLE and thyroid disease, and the presence of anti-Ro antibodies in hypothyroid mothers is associated with complete congenital heart block in infants. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Scleroderma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Systemic lupus erythematosus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Antinuclear antibodies in patients with thyroid disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any association between polymyalgia rheumatica and giant cell arteritis and thyroid disease remains controversial and thyroid function tests should be performed when clinically indicated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Polymyalgia rheumatica/giant cell arteritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there is no clear association between fibromyalgia and thyroid dysfunction, the symptoms of fibromyalgia and hypothyroidism can be similar. Thus, it is important for fibromyalgia patients to have routine thyroid function tests as part of their initial clinical screen. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fibromyalgia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnant women with anti-Ro antibodies should be screened for hypothyroidism as there is some evidence to suggest screening may identify those at a greater risk of having a child with congenital complete heart block. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antinuclear antibodies in patients with thyroid disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Vanderpump MJ, Tunbridge WMG. The epidemiology of thyroid disease. In: The Thyroid: A Fundamental and Clinical Text, 7th ed, Braverman LE, Utiger RD (Eds), Lippincott-Raven, Philadelphia 1996. p.474.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/2\">",
"      Wiseman P, Stewart K, Rai GS. Hypothyroidism in polymyalgia rheumatica and giant cell arteritis. BMJ 1989; 298:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/3\">",
"      Bowness P, Shotliff K, Middlemiss A, Myles AB. Prevalence of hypothyroidism in patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1991; 30:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/4\">",
"      Barrier JH, Abram M, Brisseau JM, et al. Autoimmune thyroid disease, thyroid antibodies and giant cell arteritis: the supposed correlation appears fortuitous. J Rheumatol 1992; 19:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/5\">",
"      Dasgupta B, Grundy E, Stainer E. Hypothyroidism in polymyalgia rheumatica and giant cell arteritis: lack of any association. BMJ 1990; 301:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/6\">",
"      Dent RG, Edwards OM. Autoimmune thyroid disease and the polymyalgia rheumatica-giant cell arteritis syndrome. Clin Endocrinol (Oxf) 1978; 9:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/7\">",
"      Ferraccioli G, Cavalieri F, Salaffi F, et al. Neuroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain). J Rheumatol 1990; 17:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/8\">",
"      Neeck G, Riedel W. Thyroid function in patients with fibromyalgia syndrome. J Rheumatol 1992; 19:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/9\">",
"      Pamuk ON, Cakir N. The frequency of thyroid antibodies in fibromyalgia patients and their relationship with symptoms. Clin Rheumatol 2007; 26:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/10\">",
"      Vianna JL, Haga HJ, Asherson RA, et al. A prospective evaluation of antithyroid antibody prevalence in 100 patients with systemic lupus erythematosus. J Rheumatol 1991; 18:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/11\">",
"      Magaro M, Zoli A, Altomonte L, et al. The association of silent thyroiditis with active systemic lupus erythematosus. Clin Exp Rheumatol 1992; 10:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/12\">",
"      Kausman D, Isenberg DA. Thyroid autoimmunity in systemic lupus erythematosus: the clinical significance of a fluctuating course. Br J Rheumatol 1995; 34:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/13\">",
"      Pyne D, Isenberg DA. Autoimmune thyroid disease in systemic lupus erythematosus. Ann Rheum Dis 2002; 61:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/14\">",
"      Miller FW, Moore GF, Weintraub BD, Steinberg AD. Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. Arthritis Rheum 1987; 30:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/15\">",
"      Baker JR Jr, Miller FW, Steinberg AD, Burman KD. Thyroid stimulating and thyrotrophin binding-inhibitory immunoglobulin activity in patients with systemic lupus erythematosus having thyroid function abnormalities. Thyroid 1991; 1:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/16\">",
"      Al Saleh J, El Sayed M, Jassim V, et al. Hypothyroidism determines the clinical and immunological manifestations of Arabs with lupus. Lupus 2008; 17:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/17\">",
"      Antonelli A, Mosca M, Fallahi P, et al. Thyroid cancer in systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab 2010; 95:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/18\">",
"      Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010; 123:183.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/19\">",
"      Namjou B, Kelly JA, Kilpatrick J, et al. Linkage at 5q14.3-15 in multiplex systemic lupus erythematosus pedigrees stratified by autoimmune thyroid disease. Arthritis Rheum 2005; 52:3646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/20\">",
"      Scofield RH, Bruner GR, Harley JB, Namjou B. Autoimmune thyroid disease is associated with a diagnosis of secondary Sj&ouml;gren's syndrome in familial systemic lupus. Ann Rheum Dis 2007; 66:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/21\">",
"      Stagnaro-Green A, Akhter E, Yim C, et al. Thyroid disease in pregnant women with systemic lupus erythematosus: increased preterm delivery. Lupus 2011; 20:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/22\">",
"      Lazarus MN, Isenberg DA. Development of additional autoimmune diseases in a population of patients with primary Sj&ouml;gren's syndrome. Ann Rheum Dis 2005; 64:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/23\">",
"      Anaya JM, Tobon GJ, Vega P, Castiblanco J. Autoimmune disease aggregation in families with primary Sj&ouml;gren's syndrome. J Rheumatol 2006; 33:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/24\">",
"      Hansen BU, Ericsson UB, Henricsson V, et al. Autoimmune thyroiditis and primary Sj&ouml;gren's syndrome: clinical and laboratory evidence of the coexistence of the two diseases. Clin Exp Rheumatol 1991; 9:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/25\">",
"      Shiroky JB, Cohen M, Ballachey ML, Neville C. Thyroid dysfunction in rheumatoid arthritis: a controlled prospective survey. Ann Rheum Dis 1993; 52:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/26\">",
"      Magnus JH, Birketvedt T, Haga HJ. A prospective evaluation of antithyroid antibody prevalence in 100 patients with rheumatoid arthritis. Scand J Rheumatol 1995; 24:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/27\">",
"      Antonelli A, Delle Sedie A, Fallahi P, et al. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. J Rheumatol 2006; 33:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/28\">",
"      H&auml;meenkorpi R, Hakala M, Ruuska P, et al. Thyroid disorder in patients with mixed connective tissue disease. J Rheumatol 1993; 20:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/29\">",
"      Bir&oacute; E, Szekanecz Z, Czirj&aacute;k L, et al. Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 2006; 25:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/30\">",
"      Marasini B, Ferrari PA, Solaro N, Selmi C. Thyroid dysfunction in women with systemic sclerosis. Ann N Y Acad Sci 2007; 1108:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/31\">",
"      Antonelli A, Ferri C, Fallahi P, et al. Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol 2007; 156:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/32\">",
"      Gordon MB, Klein I, Dekker A, et al. Thyroid disease in progressive systemic sclerosis: increased frequency of glandular fibrosis and hypothyroidism. Ann Intern Med 1981; 95:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/33\">",
"      Kahl LE, Medsger TA Jr, Klein I. Prospective evaluation of thyroid function in patients with systemic sclerosis (scleroderma). J Rheumatol 1986; 13:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/34\">",
"      Danielides S, Mavragani CP, Katsakoulas I, et al. Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma. Scand J Rheumatol 2011; 40:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/35\">",
"      Katakura M, Yamada T, Aizawa T, et al. Presence of antideoxyribonucleic acid antibody in patients with hyperthyroidism of Graves' disease. J Clin Endocrinol Metab 1987; 64:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/36\">",
"      McDermott MT, West SG, Emlen JW, Kidd GS. Antideoxyribonucleic acid antibodies in Graves' disease. J Clin Endocrinol Metab 1990; 71:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/37\">",
"      Morita S, Arima T, Matsuda M. Prevalence of nonthyroid specific autoantibodies in autoimmune thyroid diseases. J Clin Endocrinol Metab 1995; 80:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18726/abstract/38\">",
"      Spence D, Hornberger L, Hamilton R, Silverman ED. Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies. J Rheumatol 2006; 33:167.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7856 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-6660D27D4F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18726=[""].join("\n");
var outline_f18_18_18726=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THYROID DISORDERS IN CONNECTIVE TISSUE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Polymyalgia rheumatica/giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antinuclear antibodies in patients with thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42632?source=related_link\">",
"      Drug interactions with thyroid hormones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=related_link\">",
"      Pathogenesis of fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_18_18727="Oxycodone and aspirin: Pediatric drug information";
var content_f18_18_18727=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"22\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxycodone and aspirin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?37/13/38103?source=see_link\">",
"    see \"Oxycodone and aspirin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/48/32517?source=see_link\">",
"    see \"Oxycodone and aspirin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Endodan&reg;;",
"     </li>",
"     <li>",
"      Percodan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F205039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Endodan&reg;;",
"     </li>",
"     <li>",
"      Oxycodan&reg;;",
"     </li>",
"     <li>",
"      Percodan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/13/38103?source=see_link\">",
"      see \"Oxycodone and aspirin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Dosed based on total oxycodone content; titrate dose to appropriate analgesic effects; maximum daily aspirin dose: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Analgesic, moderate:",
"     </b>",
"     0.1-0.2 mg/kg/dose every 4-6 hours as needed; maximum oxycodone dose: 5 mg/dose (American Pain Society, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Analgesic, severe:",
"     </b>",
"     Initial dose: 0.2 mg/kg/dose every 4-6 hours as needed (American Pain Society, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:1 tablet every 6 hours as needed for pain; maximum aspirin dose should not exceed 4 g/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     No dosing recommendations are available for the combination product. The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR 10-50 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 75% of dose (Aronoff, 2007);",
"     <b>",
"      Note:",
"     </b>",
"     Based on the oxycodone component only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR &lt; 10 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : No data available; avoid use due to aspirin component",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Adults: Avoid use due to aspirin component",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Adults: The FDA-approved labeling does not contain dosing adjustment guidelines; use with caution; if severe impairment, avoid use of aspirin",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Oxycodone hydrochloride 4.8355 mg and aspirin 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endodan&reg;, Percodan&reg;: Oxycodone hydrochloride 4.8355 mg and aspirin 325 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F205058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer with food or milk to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate to moderately severe pain (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Percodan&reg; may be confused with Decadron, Percocet&reg;, Percogesic&reg;, Periactin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F205062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Also see individual agents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Circulatory depression, hypotension, shock",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, dysphoria, euphoria, lightheadedness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, respiratory arrest, respiratory depression",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxycodone, salicylates, other NSAIDs, or any component; severe or acute  asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); inherited or acquired bleeding disorders (including factor VII and factor IX deficiency); significant respiratory depression; hypercarbia; known or suspected paralytic ileus; children and adolescents in the presence of viral infections (chickenpox or flu symptoms) with or without fever, due to a potential association with Reye's syndrome",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Use with caution in patients with impaired hepatic or renal function, platelet or bleeding disorders, erosive gastritis, peptic ulcer, or heavy alcohol use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxycodone: Use with caution in patients with hypersensitivity to other phenanthrene derivative opioid agonists (morphine, codeine, hydrocodone, hydromorphone, oxymorphone, levorphanol); discontinue  immediately if symptoms of allergic or hypersensitivity reactions occur. Use with caution in patients with adrenal insufficiency (Addison&rsquo;s disease), biliary tract disease, pancreatitis, CNS depression, acute alcoholism, delirium tremens,  kyphoscoliosis with respiratory depression, hypothyroidism (myxedema), severe liver, pulmonary or renal impairment, urinary stricture, prostatic hypertrophy, or seizures. Use caution when combining with other CNS depressants (eg centrally acting antiemetics, general anesthetics, phenothiazines, sedative-hypnotics) as there may be additive CNS effects. If combined therapy is needed, consider reducing the dose of one or both agents.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oxycodone may cause CNS depression which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Respiratory depression may occur even at therapeutic doses; use with extreme caution in patients with pre-existing respiratory depression, significantly decreased respiratory reserve, hypoxia, hypercapnia, respiratory diseases (including asthma, emphysema, significant COPD, or cor pulmonale), other obstructive pulmonary disease, kyphoscoliosis, or other skeletal disorder which may alter respiratory function.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oxycodone may exaggerate elevated intracranial pressure; use with extreme caution in patients with head injury, intracranial lesions, or elevated ICP. Hypotension may occur; especially in hypovolemic patients or those receiving medications that compromise vasomotor tone or exaggerate hypotensive effects (including phenothiazines); use with extreme caution in patients with circulatory shock. Orthostatic hypotension may occur in ambulatory patients. Oxycodone may obscure diagnosis or clinical course of patients with acute abdominal conditions; has been shown to decrease gastrointestinal motility; use with caution in postoperative patients especially after intra-abdominal surgery.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Physical and psychological dependence may occur; abrupt discontinuation after prolonged use may result in withdrawal symptoms; warn patients of possible impairment of alertness or physical coordination; concurrent use of agonist/antagonist analgesics (ie, pentazocine, nalbuphine, and butorphanol) may precipitate withdrawal symptoms and/or reduce analgesic efficacy in patients following prolonged therapy with mu opioid agonists such as oxycodone. Infants born to women physically dependent on opioids will also be physically dependent and may experience respiratory difficulties or opioid withdrawal symptoms (neonatal abstinence syndrome). Symptoms of opiate withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, tremors, or vomiting. High potential for abuse; healthcare providers should be alert to problems of abuse, misuse, and diversion.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F205050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically gastrointestinal adverse events.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Aspirin may enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Aspirin may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in patients receiving ticagrelor.  Canadian recommendations are to avoid daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiludronate: Aspirin may decrease the serum concentration of Tiludronate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of OxyCODONE. Management: A reduced oxycodone dose may be necessary with concurrent voriconazole.  Increased frequency and duration of monitoring for oxycodone-related adverse effects is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aspirin may increase renal excretion of vitamin C and may decrease serum folate levels",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (oxycodone); D (aspirin) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory rate, mental status, blood pressure; signs of misuse, abuse, and addiction",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Inhibits prostaglandin synthesis, acts on the hypothalamus heat-regulating center to reduce fever, blocks prostaglandin synthetase action which prevents formation of the platelet-aggregating substance thromboxane A",
"     <sub>",
"      2",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxycodone: Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/48/32517?source=see_link\">",
"      see \"Oxycodone and aspirin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause postural hypotension (use caution when changing positions from lying or sitting to standing); watch for bleeding gums or signs of GI bleeding (bright red blood in emesis or stool, coffee ground-like emesis, black tarry stools); notify physician if ringing in the ears, persistent GI pain, GI bleeding, or changes in behavior (along with nausea and vomiting) occur. Avoid alcohol; report the use of other prescription and nonprescription medications to your physician and pharmacist. May be habit-forming; do not discontinue abruptly if therapy lasts more than a few weeks; dose should be tapered to prevent withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One generic tablet contains &sim;5 mg oxycodone as combined salt",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,\" 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12668 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18727=[""].join("\n");
var outline_f18_18_18727=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205038\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205039\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054662\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054656\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205025\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205010\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205058\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054667\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054666\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205064\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205062\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054670\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054655\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054654\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205050\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205018\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054672\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205020\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205032\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054661\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054653\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054669\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054660\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054671\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12668\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12668|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/13/38103?source=related_link\">",
"      Oxycodone and aspirin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/48/32517?source=related_link\">",
"      Oxycodone and aspirin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_18_18728="Genital Chlamydia trachomatis infections in men";
var content_f18_18_18728=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genital Chlamydia trachomatis infections in men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18728/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18728/contributors\">",
"     Jonathan M Zenilman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18728/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18728/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18728/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18728/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/18/18728/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydia trachomatis, a small gram-negative bacterium, is the most common cause of bacterial sexually transmitted disease (STD) in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/1\">",
"     1",
"    </a>",
"    ]. A significant proportion of patients are asymptomatic, thereby providing an ongoing reservoir for infection. The most frequent clinical manifestation of chlamydial infection in men is urethritis.",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, and diagnosis of genital C. trachomatis infection in men will be reviewed here. Other types of C. trachomatis infection, including genital infections in women, lymphogranuloma venereum, and endemic trachoma, an ocular infection spread by direct contact and seen commonly in the developing world, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8409?source=see_link\">",
"     \"Epidemiology, diagnosis, and management of trachoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of chlamydia infections is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=see_link\">",
"     \"Treatment of Chlamydia trachomatis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. trachomatis is a small gram-negative bacterium with unique biologic properties that distinguish it from all other living organisms. It is an obligate intracellular parasite that has a distinct life-cycle that consists of two major phases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The small elementary bodies attach and penetrate into cells, changing into the metabolically active form, called the reticulate body, within six to eight hours. These forms create large inclusions within cells.",
"     </li>",
"     <li>",
"      The reticulate bodies then reorganize into small elementary bodies, and within two to three days the cell ruptures, releasing newly formed elementary bodies. Release of the elementary bodies initiates the replicative process, since this is the form which can infect new epithelial cells. The long growth cycle explains why prolonged courses of treatment are necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chlamydia cannot be cultured on artificial media; traditionally tissue culture has been required to establish a diagnosis. Rapid and inexpensive screening tests are now available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=see_link\">",
"     \"Screening for Chlamydia trachomatis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One critical feature of chlamydial organisms is that immunity to infection is not long-lived. As a result, reinfection or persistent infection is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of C. trachomatis infections in men is difficult to determine. It is common to screen women for chlamydia and to empirically treat men [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/2\">",
"     2",
"    </a>",
"    ]. Although most chlamydia-associated morbidity is in women, infections in men provide the reservoir for new and recurrent infections in women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, it is important to determine prevalence in various patient populations to target cost-effective screening programs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/4\">",
"     4",
"    </a>",
"    ]. Availability of non-invasive based screening with NAATs may lead to more widespread screening [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have shown chlamydia infection to be frequent, especially in younger age groups,",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    minorities, MSM, and incarcerated populations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective cohort study from North Carolina, the rate of chlamydia infection in women was 662 cases per 100,000 person-years compared to 449 cases per 100,000 person-years in men [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective cohort study of 14,322 individuals between the ages of 18 and 26 across the United States, interviewed and tested at home, found a prevalence of chlamydial infection in 3.7 percent of men; the highest prevalence was in African American men at 11 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Urine-based screening with NAAT of 1434 asymptomatic high school students in Baltimore and Denver found an overall prevalence of 6.8 percent for chlamydia infection [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 9662 men at an STD clinic in Rochester, NY, demonstrated a 4.9 percent prevalence employing a direct fluorescent antibody (DFA) test on urethral swabs [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of published data from national sources that included surveys of adolescents, MSM, correctional facilities and data from the National Health and Nutrition Examination Survey (NHANES 1999 to 2002), found that the burden of chlamydia infection was greatest among young men aged 20 to 24 years [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/6\">",
"       6",
"      </a>",
"      ]. With the exception of MSM, chlamydia infections were disproportionately higher in black and Hispanic men when compared to white men. Overall chlamydia rates were highest in adult corrections facilities; the 2005 prevalence rate among men aged 21 to 25 years was 7.8 percent.",
"     </li>",
"     <li>",
"      Screening 1338 asymptomatic men and women at four United States military sites, the overall prevalence of chlamydia infection was 4.2 percent, 4.1 percent in 1024 men and 4.4 percent in 314 women [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Outside the United States",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In male military recruits from Stockholm, the prevalence of C. trachomatis was 10 percent by culture; all cases occurred in men 17 to 18 years of age and only one was symptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/13\">",
"       13",
"      </a>",
"      ]. The rate of infection among 798 military recruits in Scotland was 9.8 percent; 88 percent of these men were asymptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chlamydia infection was detected in 15.4 percent of 378 men seen at an STD clinic in the United Kingdom using polymerase chain reaction (PCR) on urine [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population-based study in China estimated the prevalence of C. trachomatis infection at the surprisingly high rate of 2.1 per 100 population; unprotected sex with a commercial sex worker was a significant risk factor for infection among men aged 20 to 44 years [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less is known about the risk factors for Chlamydia infection in men than in women. One study in the Netherlands aimed to validate selective screening criteria for Chlamydia infection through population based screening of 21,000 men and women 15 to 29 years of age through home based urine testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/17\">",
"     17",
"    </a>",
"    ]. The prevalence of Chlamydia was 2.6 percent in women and 2.0 percent in men. Infection was associated with young age, multiple sex partners,",
"    <span class=\"nowrap\">",
"     low/intermediate",
"    </span>",
"    education, low condom use, and complaints of frequent urination in men.",
"   </p>",
"   <p>",
"    Since asymptomatic infection is common in men, screening should be offered to those patients who have risk factors, even if they do not complain of symptoms consistent with urethritis or proctitis. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Definition and clinical manifestations'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Chlamydial proctitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship and transmissibility of C. trachomatis between sexual partners is another area that has been difficult to study. Several reports suggest that asymptomatic partners facilitate the transmission of this pathogen. As an example, 20 of 31 women (65 percent) exposed to male sexual partners with chlamydia infection acquired the pathogen compared to 33 of 45 (73 percent) exposed to a partner with gonorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHLAMYDIAL (NON-GONOCOCCAL) URETHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethritis in men has traditionally been classified as gonococcal and non-gonococcal. C. trachomatis is the most commonly identified cause of non-gonococcal urethritis (NGU), but the number of cases due to this pathogen appears to be decreasing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/2\">",
"     2",
"    </a>",
"    ]. Traditional teaching held that C. trachomatis was responsible for approximately 50 percent of cases of NGU [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/1\">",
"     1",
"    </a>",
"    ], but in a randomized, controlled trial of two regimens for the treatment of NGU, chlamydia were found to account for only 16 to 24 percent of infections, using culture as the diagnostic approach [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/19\">",
"     19",
"    </a>",
"    ]. However, as noted above, screening programs for chlamydia are more often aimed at women, and men are frequently treated empirically. Thus, it is safe to assume that the number of NGU cases is at least double that of diagnosed chlamydial infections in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Definition and clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;NGU is a clinical syndrome defined by two features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of urethritis including urethral discharge",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dysuria",
"     </li>",
"     <li>",
"      Urethral inflammation documented by the presence of a mucopurulent discharge or leukocytes on Gram stain (",
"      <a class=\"graphic graphic_picture graphicRef56547 \" href=\"UTD.htm?37/63/38898\">",
"       picture 1",
"      </a>",
"      ). However, not all patients with symptomatic urethritis have elevated levels of urethral leukocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis of urethritis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with NGU typically present with a mucoid or watery discharge, and dysuria is often a prominent complaint. The incubation period is variable but is typically 5 to 10 days after exposure. The incubation period for gonococcal urethritis tends to be shorter (2 to 7 days) and the urethral discharge is typically more copious and purulent. However, these syndromes frequently overlap and cannot reliably be distinguished on clinical grounds only.",
"   </p>",
"   <p>",
"    Five to 10 percent of cases of gonococcal urethritis and up to 42 percent of NGU are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. An important clinical consequence of asymptomatic infection is transmission of infection to other individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis of urethritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In careful studies, chlamydia accounts for 19 to 31 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/23\">",
"     23",
"    </a>",
"    ]. The other major etiologies to consider are Mycoplasma genitalium, Herpes simplex virus, Trichomonas vaginalis, and Ureaplasma urealyticum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most comprehensive study to evaluate the etiologic spectrum of nongonococcal urethritis tested 329 symptomatic men and 307 asymptomatic controls for C. trachomatis, M. genitalium, HSV types 1 and 2, T. vaginalis, U. urealyticum, U. parvum, Gardnerella vaginalis, and adenoviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/20\">",
"     20",
"    </a>",
"    ]. The study was significant for the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      M. genitalium was the only potential pathogen identified in 9 percent of cases and 1 percent of controls, which provides important confirmatory evidence of the role of this organism in a modest proportion of NGU cases.",
"     </li>",
"     <li>",
"      HSV and adenoviruses were isolated in 3 and 4 percent of cases, respectively. These pathogens were found more often in MSM and in association with a history of insertive oral sex whereas C. trachomatis and M. genitalium were associated with sex with women and unprotected vaginal sex. Furthermore, most of the herpetic cases were related to HSV-1 in the absence of any visible ulcerative lesions.",
"     </li>",
"     <li>",
"      A urethral polymorphonuclear count of greater than or equal to 5 leukocytes had inadequate sensitivity to exclude urethral infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study suggests that some pathogens of urethritis can be acquired by fellatio [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/20\">",
"     20",
"    </a>",
"    ]. Insertive oral sex was also a significant risk factor in pathogen-negative NGU, suggesting that the oropharynx may be a significant source of other bacterial and viral pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/20,26\">",
"     20,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The true incidence of U. urealyticum infections is controversial since these organisms can also be found as commensals in hosts with no evidence of disease. A case-control study in heterosexual men visiting an urban STD clinic found that isolation of M. genitalium carried a 6.5-fold increased risk of NGU, while U. urealyticum was not associated with these symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/27\">",
"     27",
"    </a>",
"    ]. Lack of association of U. urealyticum with NGU urethritis was also demonstrated in the above study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trichomonas is being increasingly recognized as an etiology of urethritis syndrome with improved diagnostic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/23\">",
"     23",
"    </a>",
"    ]. In men, a wet preparation is insensitive, and culture testing of an urethral swab, urine, and semen is required for optimal sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethritis is documented on the basis of any of the following signs and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucopurulent or purulent discharge",
"     </li>",
"     <li>",
"      Gram stain of urethral secretions demonstrating &gt;5",
"      <span class=\"nowrap\">",
"       WBC/hpf.",
"      </span>",
"     </li>",
"     <li>",
"      Positive leukocyte esterase test on first-void urine or microscopic examination of first-void urine sediment demonstrating &gt;10",
"      <span class=\"nowrap\">",
"       WBC/hpf.",
"      </span>",
"      The &ldquo;first-void urine&rdquo; is the initial urine sample voided after awakening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once urethritis is suspected, testing for the specific etiologic agent is recommended since both chlamydia and gonorrhea are reportable diseases; diagnosis also prompts identification and treatment of the partner(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Available diagnostic tests for C. trachomatis include culture, direct immunofluorescence, ELISA, and nucleic acid amplification techniques (NAATs). The most sensitive and specific of these tests is NAATS, which can be performed on urethral specimens and on urine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Urine based diagnostic testing decreases costs and time to test completion. They also avoid the patient discomfort associated with urethral sampling and may thereby improve patient acceptance of diagnostic testing.",
"   </p>",
"   <p>",
"    Rectal chlamydial infection in persons who engage in receptive anal intercourse can be diagnosed by testing a rectal swab specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28\">",
"     28",
"    </a>",
"    ]. NAAT testing has not been cleared by the Food and Drug Administration (FDA) for use with rectal swabs. However, some laboratories have met testing validation requirements under the Clinical Laboratory Improvement Amendment (CLIA) regulations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review pooled data from 29 studies to assess the sensitivity and specificity of NAATs for C. trachomatis infection in urine specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/31\">",
"     31",
"    </a>",
"    ]. Summary estimates for sensitivity and specificity were calculated for urine and urethral sampling for three NAAT methods (using PCR, TMA, or SDA). The analysis demonstrated that the sensitivity and specificity of non-invasive testing was comparable to invasive testing, although more data was available for analysis on PCR testing than the other two methods as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For 12 studies of the PCR assay, the pooled sensitivity and specificity were 84 and 99 percent for urine samples and 88 and 99 percent for urethral samples.",
"     </li>",
"     <li>",
"      For the two studies of the TMA assay, the pooled sensitivity and specificity were 88 and 99 percent for urine samples and 96 and 99 percent for urethral samples.",
"     </li>",
"     <li>",
"      For the one study of the SDA assay, the sensitivity and specificity were 93 and 94 percent for urine samples and 92 and 96 percent for urethral samples.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until the development of nucleic acid based diagnostic tests, expensive tissue culture of urethral swab specimens was the \"gold standard\" for diagnosing chlamydia. However, sensitivity for asymptomatic urethral infection was estimated to be only 50 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OTHER CHLAMYDIAL SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. trachomatis can cause other syndromes in men including proctitis, epididymitis, some cases of prostatitis, and reactive arthritis (formerly Reiter syndrome). Unlike in women, asymptomatic chlamydial infection has not been associated with infertility in men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chlamydial proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydial proctitis, defined as inflammation of the distal rectal mucosa, is relatively uncommon and occurs almost exclusively in men who have sex with men (MSM) who have had receptive rectal intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Symptoms include anal rectal pain, discharge, tenesmus, and constipation. Some individuals with chlamydial proctitis are asymptomatic or minimally symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/9,22,35\">",
"     9,22,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An anoscopic exam is often useful to demonstrate mucosal friability, internal lesions, masses or polyps and to obtain rectal discharge for diagnostic specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of 316 diagnosed rectal chlamydial infections in MSM who underwent screening for sexually transmitted diseases, 86 percent were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/22\">",
"     22",
"    </a>",
"    ]. Futhermore, rectal chlamydia was more common than urethral chlamydia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of proctitis in MSM includes N. gonorrhoeae, herpes simplex virus, and Treponema pallidum infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/36\">",
"     36",
"    </a>",
"    ]. The frequency of these causes was evaluated in a review of 101 episodes of proctitis among MSM in San Francisco; anoscopy was performed and specimens obtained that were tested for the above organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/36\">",
"     36",
"    </a>",
"    ]. The following frequency of causes was noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      None &mdash; 45 percent",
"     </li>",
"     <li>",
"      Gonorrhea only &mdash; 20 percent",
"     </li>",
"     <li>",
"      Herpes simplex only &mdash; 13 percent",
"     </li>",
"     <li>",
"      Chlamydia only &mdash; 11 percent",
"     </li>",
"     <li>",
"      Mixed infections &mdash; 10 percent, including 8 percent with Chlamydia",
"     </li>",
"     <li>",
"      Syphilis only &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lymphogranuloma venereum (LGV), which is caused by C. trachomatis serovars L1, L2, and L3, is rare in developed countries. However, an outbreak of LGV proctitis in 15 MSM occurred in 2003 in the Netherlands [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/37\">",
"     37",
"    </a>",
"    ]. All of the patients had a history of sexually transmitted diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Epididymitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;N. gonorrhoeae or C. trachomatis are the most frequent pathogens in epididymitis among sexually active men &lt;35 years of age. N. gonorrhoeae was responsible for 57 percent of cases of acute epididymitis, C. trachomatis 34 percent, and both pathogens 13 percent in one study of 144 men from South Africa, 93 percent of whom were &lt;35 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/38\">",
"     38",
"    </a>",
"    ]. In another study of 11 young men with epididymitis, PCR was positive for C. trachomatis in nine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/39\">",
"     39",
"    </a>",
"    ]. Escherichia coli has also been implicated in epididymitis in homosexual men who are the insertive partners during anal intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic urethritis frequently accompanies sexually transmitted epididymitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28\">",
"     28",
"    </a>",
"    ]. Risk factors for nonsexually transmitted epididymitis include age &gt;35 years, recent urinary tract instrumentation or surgery, and anatomic abnormalities; associated urinary tract infections caused by gram-negative enteric organisms are common [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with acute epididymitis typically have unilateral testicular pain and tenderness, hydrocele, and palpable swelling of the epididymis. Occasionally, C. trachomatis infection can be misdiagnosed as a testicular malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/40\">",
"     40",
"    </a>",
"    ]. Young men with suspected acute epididymitis should be tested for chlamydia and gonococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urgent testing for testicular torsion is indicated when the onset of pain is sudden and severe, since testicular viability may be compromised by late diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation for epididymitis should include one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gram stain of urethral secretions demonstrating &gt;5",
"      <span class=\"nowrap\">",
"       WBC/hpf",
"      </span>",
"     </li>",
"     <li>",
"      Positive leukocytes esterase test on first-void urine or microscopic examination of first-void urine sediment demonstrating &gt;10",
"      <span class=\"nowrap\">",
"       WBC/hpf.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radionuclide scanning of the scrotum is the most accurate radiologic method of diagnosis, although it is not routinely available. Ultrasonography has a sensitivity of 70 percent and specificity of 99 percent in diagnosing acute epididymitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of epididymitis includes testicular torsion, abscess, infarction, testicular cancer, and epididymitis secondary to other infectious etiologies (TB and fungal pathogens).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prostatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports from outside of the United States suggest that C. trachomatis may be an etiology in some cases of chronic prostatitis, although this area remains highly speculative. As an example, chlamydia antigen was detected significantly more frequently in urine and prostate secretions from 55 patients with chronic prostatitis compared to 35 controls (25 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/41\">",
"     41",
"    </a>",
"    ]. In another study of 42 patients with evidence of inflammation in prostatic secretions, chlamydial antigen was present in 14 percent of urethral samples and 21 percent of expressed prostatic secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/42\">",
"     42",
"    </a>",
"    ]. In situ hybridization for chlamydia was positive in 21 percent of prostatic secretions in a third series of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1 percent of men with urethritis develop reactive arthritis, and approximately one-third of these patients have the complete manifestations formerly referred to as Reiter syndrome (arthritis, uveitis, and urethritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    C. trachomatis appears to be the most common inciting pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/45\">",
"     45",
"    </a>",
"    ]. In one series of 113 patients with Reiter syndrome, urethral cultures were positive for chlamydia in 39 percent overall and 69 percent of patients with signs of urethral inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newer diagnostic techniques have facilitated the detection of chlamydial DNA and RNA in synovial tissue, although the interpretation of these results is not clear. As an example, seven of nine patients with Reiter syndrome had a positive in situ hybridization test for chlamydial RNA from samples of synovial tissue compared to three of 13 patients without Reiter syndrome (the cause of the arthritis in these three patients was not otherwise defined) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/47\">",
"     47",
"    </a>",
"    ]. In another study, PCR detected chlamydial DNA on stored synovial tissue biopsies from five of eight patients with sexually-acquired reactive arthritis and one control patient with another form of arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18728/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       \"Patient information: Chlamydia and gonorrhea (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"       \"Patient information: Chlamydia (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/0/30721?source=see_link\">",
"       \"Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5336137\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chlamydia trachomatis is the most common cause of bacterial sexually transmitted disease (STD) in both men and women. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      C. trachomatis, a small gram-negative bacterium, is an obligate intracellular parasite. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of C. trachomatis infections in men is difficult to determine because it is common practice to screen women for chlamydia and to empirically treat men. Although most chlamydia-associated morbidity is seen in women, infections in men provide the reservoir for new and recurrent infections in women. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urethritis in men has traditionally been classified as gonococcal and non-gonococcal in etiology. C. trachomatis is the most commonly identified cause of non-gonococcal urethritis (NGU), Patients with NGU typically present with a mucoid or watery discharge with complain of dysuria. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chlamydial (non-gonococcal) urethritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The other major etiologies of NGU include Mycoplasma genitalium, Herpes simplex virus, Trichomonas vaginalis, and Ureaplasma urealyticum. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis of urethritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of urethritis is based on a Gram stain of penile discharge demonstrating &gt;5",
"      <span class=\"nowrap\">",
"       WBCs/high",
"      </span>",
"      power field or a positive leukocyte esterase test on first-void urine or a positive microscopic examination of urinary sediment demonstrating &gt;10",
"      <span class=\"nowrap\">",
"       WBCs/high",
"      </span>",
"      power field. The &ldquo;first-void urine&rdquo; is the initial urine sample voided after awakening. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once urethritis is suspected, testing for Chlamydia and Neisseria gonorrhea is indicated. The most sensitive and specific diagnostic method for either pathogen is nucleic acid amplification testing, which can be performed on urethral or urine specimens. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      C. trachomatis can cause other syndromes in men including proctitis, epididymitis, and reactive arthritis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Other chlamydial syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of chlamydial proctitis include anal rectal pain, discharge, tenesmus, and constipation. Some individuals with chlamydial proctitis are asymptomatic or minimally symptomatic. An anoscopic exam is often useful to demonstrate mucosal friability, internal lesions, masses or polyps and to obtain diagnostic specimens. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Chlamydial proctitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men with acute epididymitis typically have unilateral testicular pain and tenderness, hydrocele, and palpable swelling of the epididymis. Radionuclide scanning of the scrotum is the preferred diagnostic test over ultrasound, where available. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Epididymitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 1 percent of men with urethritis develop an inflammatory syndrome characterized by reactive arthritis, uveitis and urethritis. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Reactive arthritis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/1\">",
"      Stamm WE. Chlamydia trachomatis infections: progress and problems. J Infect Dis 1999; 179 Suppl 2:S380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/2\">",
"      Burstein GR, Zenilman JM. Nongonococcal urethritis--a new paradigm. Clin Infect Dis 1999; 28 Suppl 1:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/3\">",
"      Gaydos CA, Ferrero DV, Papp J. Laboratory aspects of screening men for Chlamydia trachomatis in the new millennium. Sex Transm Dis 2008; 35:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/4\">",
"      Gift TL, Blake DR, Gaydos CA, Marrazzo JM. The cost-effectiveness of screening men for Chlamydia trachomatis: a review of the literature. Sex Transm Dis 2008; 35:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/5\">",
"      Burstein GR, Waterfield G, Joffe A, et al. Screening for gonorrhea and chlamydia by DNA amplification in adolescents attending middle school health centers. Opportunity for early intervention. Sex Transm Dis 1998; 25:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/6\">",
"      Satterwhite CL, Joesoef MR, Datta SD, Weinstock H. Estimates of Chlamydia trachomatis infections among men: United States. Sex Transm Dis 2008; 35:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/7\">",
"      Rietmeijer CA, Hopkins E, Geisler WM, et al. Chlamydia trachomatis positivity rates among men tested in selected venues in the United States: a review of the recent literature. Sex Transm Dis 2008; 35:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/8\">",
"      Michelson KN, Thomas JC, Boyd C, Janssens AH. Chlamydia trachomatis infection in a rural population: the importance of screening men. Int J STD AIDS 1999; 10:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/9\">",
"      Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004; 291:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/10\">",
"      Joffe A, Rietmeijer CA, Chung SE, et al. Screening asymptomatic adolescent men for Chlamydia trachomatis in school-based health centers using urine-based nucleic acid amplification tests. Sex Transm Dis 2008; 35:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/11\">",
"      Urban MA, Coury-Doniger P, Reichman RC. Results of a screening program for Chlamydia trachomatis infection in men attending a sexually transmitted diseases clinic. Sex Transm Dis 1997; 24:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/12\">",
"      Brodine SK, Shafer MA, Shaffer RA, et al. Asymptomatic sexually transmitted disease prevalence in four military populations: application of DNA amplification assays for Chlamydia and gonorrhea screening. J Infect Dis 1998; 178:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/13\">",
"      Larsson S, Rud&eacute;n AK, Bygdeman SM. Screening for Chlamydia trachomatis genital infection in young men in Stockholm. Int J STD AIDS 1990; 1:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/14\">",
"      McKay L, Clery H, Carrick-Anderson K, et al. Genital Chlamydia trachomatis infection in a subgroup of young men in the UK. Lancet 2003; 361:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/15\">",
"      Higgins SP, Klapper PE, Struthers JK, et al. Detection of male genital infection with Chlamydia trachomatis and Neisseria gonorrhoeae using an automated multiplex PCR system (Cobas Amplicor). Int J STD AIDS 1998; 9:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/16\">",
"      Parish WL, Laumann EO, Cohen MS, et al. Population-based study of chlamydial infection in China: a hidden epidemic. JAMA 2003; 289:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/17\">",
"      G&ouml;tz HM, van Bergen JE, Veldhuijzen IK, et al. A prediction rule for selective screening of Chlamydia trachomatis infection. Sex Transm Infect 2005; 81:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/18\">",
"      Lin JS, Donegan SP, Heeren TC, et al. Transmission of Chlamydia trachomatis and Neisseria gonorrhoeae among men with urethritis and their female sex partners. J Infect Dis 1998; 178:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/19\">",
"      Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. JAMA 1995; 274:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/20\">",
"      Bradshaw CS, Tabrizi SN, Read TR, et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis 2006; 193:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/21\">",
"      McNagny SE, Parker RM, Zenilman JM, Lewis JS. Urinary leukocyte esterase test: a screening method for the detection of asymptomatic chlamydial and gonococcal infections in men. J Infect Dis 1992; 165:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/22\">",
"      Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005; 41:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/23\">",
"      Romanowski B, Talbot H, Stadnyk M, et al. Minocycline compared with doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis. Ann Intern Med 1993; 119:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/24\">",
"      Krieger JN, Verdon M, Siegel N, et al. Risk assessment and laboratory diagnosis of trichomoniasis in men. J Infect Dis 1992; 166:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/25\">",
"      Horner P, Thomas B, Gilroy CB, et al. Role of Mycoplasma genitalium and Ureaplasma urealyticum in acute and chronic nongonococcal urethritis. Clin Infect Dis 2001; 32:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/26\">",
"      Handsfield HH. Nongonococcal urethritis: a few answers but mostly questions. J Infect Dis 2006; 193:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/27\">",
"      Totten PA, Schwartz MA, Sj&ouml;str&ouml;m KE, et al. Association of Mycoplasma genitalium with nongonococcal urethritis in heterosexual men. J Infect Dis 2001; 183:269.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on January 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/29\">",
"      Quinn TC, Welsh L, Lentz A, et al. Diagnosis by AMPLICOR PCR of Chlamydia trachomatis infection in urine samples from women and men attending sexually transmitted disease clinics. J Clin Microbiol 1996; 34:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/30\">",
"      Chernesky MA, Lee H, Schachter J, et al. Diagnosis of Chlamydia trachomatis urethral infection in symptomatic and asymptomatic men by testing first-void urine in a ligase chain reaction assay. J Infect Dis 1994; 170:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/31\">",
"      Cook RL, Hutchison SL, &Oslash;stergaard L, et al. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005; 142:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/32\">",
"      Quinn TC, Gaydos C, Shepherd M, et al. Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA 1996; 276:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/33\">",
"      Rompalo AM, Suchland RJ, Price CB, Stamm WE. Rapid diagnosis of Chlamydia trachomatis rectal infection by direct immunofluorescence staining. J Infect Dis 1987; 155:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/34\">",
"      Boisvert JF, Koutsky LA, Suchland RJ, Stamm WE. Clinical features of Chlamydia trachomatis rectal infection by serovar among homosexually active men. Sex Transm Dis 1999; 26:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/35\">",
"      Rompalo AM. Diagnosis and treatment of sexually acquired proctitis and proctocolitis: an update. Clin Infect Dis 1999; 28 Suppl 1:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/36\">",
"      Klausner JD, Kohn R, Kent C. Etiology of clinical proctitis among men who have sex with men. Clin Infect Dis 2004; 38:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/37\">",
"      Nieuwenhuis RF, Ossewaarde JM, G&ouml;tz HM, et al. Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar l2 proctitis in The Netherlands among men who have sex with men. Clin Infect Dis 2004; 39:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/38\">",
"      Hoosen AA, O'Farrell N, van den Ende J. Microbiology of acute epididymitis in a developing community. Genitourin Med 1993; 69:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/39\">",
"      Eley A, Oxley KM, Spencer RC, et al. Detection of Chlamydia trachomatis by the polymerase chain reaction in young patients with acute epididymitis. Eur J Clin Microbiol Infect Dis 1992; 11:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/40\">",
"      Ward AM, Rogers JH, Estcourt CS. Chlamydia trachomatis infection mimicking testicular malignancy in a young man. Sex Transm Infect 1999; 75:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/41\">",
"      Mutlu N, Mutlu B, Culha M, et al. The role of Chlamydia trachomatis in patients with non-bacterial prostatitis. Int J Clin Pract 1998; 52:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/42\">",
"      Ostaszewska I, Zdrodowska-Stefanow B, Badyda J, et al. Chlamydia trachomatis: probable cause of prostatitis. Int J STD AIDS 1998; 9:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/43\">",
"      G&uuml;m&uuml; B, Sengil AZ, Solak M, et al. Evaluation of non-invasive clinical samples in chronic chlamydial prostatitis by using in situ hybridization. Scand J Urol Nephrol 1997; 31:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/44\">",
"      Keat A. Extra-genital Chlamydia trachomatis infection as sexually-acquired reactive arthritis. J Infect 1992; 25 Suppl 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/45\">",
"      Barth WF, Segal K. Reactive arthritis (Reiter's syndrome). Am Fam Physician 1999; 60:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/46\">",
"      Kousa M, Saikku P, Richmond S, Lassus A. Frequent association of chlamydial infection with Reiter's syndrome. Sex Transm Dis 1978; 5:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/47\">",
"      Rahman MU, Cheema MA, Schumacher HR, Hudson AP. Molecular evidence for the presence of chlamydia in the synovium of patients with Reiter's syndrome. Arthritis Rheum 1992; 35:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18728/abstract/48\">",
"      Taylor-Robinson D, Gilroy CB, Thomas BJ, Keat AC. Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet 1992; 340:81.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7590 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18728=[""].join("\n");
var outline_f18_18_18728=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5336137\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - United States",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Outside the United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHLAMYDIAL (NON-GONOCOCCAL) URETHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Definition and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis of urethritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OTHER CHLAMYDIAL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chlamydial proctitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Epididymitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prostatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5336137\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7590\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7590|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/63/38898\" title=\"picture 1\">",
"      Chlamydia urethral Gram stain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8409?source=related_link\">",
"      Epidemiology, diagnosis, and management of trachoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=related_link\">",
"      Lymphogranuloma venereum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/0/30721?source=related_link\">",
"      Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=related_link\">",
"      Screening for Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=related_link\">",
"      Treatment of Chlamydia trachomatis infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_18_18729="Anatomy common femoral artery";
var content_f18_18_18729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51298%7EEM%2F65123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51298%7EEM%2F65123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Anatomy common femoral artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 610px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    External landmarks for access to the femoral vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 577px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The midinguinal point lying half-way between the anterior superior iliac spine and the symphysis pubis marks the normal location of the femoral artery. The femoral vein lies just medial to the artery. Remember that pulsations will be felt in the femoral vein in cardiac arrest patients receiving chest compressions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18729=[""].join("\n");
var outline_f18_18_18729=null;
var title_f18_18_18730="Parenteral nutrition-associated liver disease in infants";
var content_f18_18_18730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parenteral nutrition-associated liver disease in infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18730/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18730/contributors\">",
"     Kathleen M Gura, PharmD, BCNSP, FASHP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18730/contributors\">",
"     Scott A Elisofon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18730/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18730/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18730/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/18/18730/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/18/18730/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/18/18730/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial proportion of infants who depend upon parenteral nutrition because of intestinal failure develop cholestatic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/1\">",
"     1",
"    </a>",
"    ]. The disorder is particularly common among infants with a history of prematurity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bowel resection (short bowel syndrome), and is a major cause of morbidity, liver transplantation, and death in these patients.",
"   </p>",
"   <p>",
"    Parenteral nutrition-associated liver disease is less common and generally less severe among older children and adults, but may occur in those undergoing long-term treatment with parenteral nutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral nutrition-associated liver disease (PNALD) is also known as parenteral nutrition-associated cholestasis (PNAC). PNALD is defined as cholestasis occurring in the setting of parenteral nutrition (PN), if other specific causes of liver injury have been excluded. Cholestasis is usually defined as an elevated serum conjugated bilirubin &ge;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (34.2",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term intestinal failure-associated liver disease (IFALD) has gained popularity in describing the cholestatic liver disease seen in patients with intestinal failure (eg, short bowel syndrome) receiving long-term PN. Unlike PNALD, IFALD acknowledges that cholestasis is multifactorial in its etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PNALD is seen in 40 to 60 percent of children who receive long-term PN and 15 to 40 percent of adults on home PN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe and progressive PNALD is most common in infants and neonates, particularly those with short bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In one review, PNALD was seen in 14 percent of infants receiving PN for two to four weeks, 43 percent of those receiving PN for four to eight weeks, 72 percent of those receiving PN for 8 to 14 weeks, and 85 percent of those receiving PN for more than 14 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H5#H5\">",
"     \"Chronic complications of the short bowel syndrome in children\", section on 'Liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of PNALD is uncertain but is probably multifactorial. Components of the PN probably act as toxins, but bacterial endotoxins and lack of enteral feeding are also thought to play significant roles [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/7\">",
"     7",
"    </a>",
"    ]. The risk factors described below are closely correlated. For example, premature infants are also more likely to have complications, such as necrotizing enterocolitis, that result in short bowel syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immature liver function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for PNALD include prematurity, low birth weight, and intrauterine growth restriction, suggesting that immaturity of the liver is a predisposing factor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, birth weight &lt;500 g was associated with a 30-fold increase in risk for PNALD as compared with birth weight &gt;750 g [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a group of 62 premature infants with birthweight &lt;2000 g, cholestasis developed in 50 percent of those with birthweight &lt;1000 g but only in 7 percent of those with birthweight &gt;1500 to 2000 g [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/10\">",
"       10",
"      </a>",
"      ]. The incidence of cholestasis approached 90 percent for infants on PN more than 90 days, combining both birthweight categories.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The immature liver appears to be more sensitive to the other pathogenic factors discussed in the following sections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inflammatory mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes of sepsis, including catheter-related sepsis, are associated with the severity of liver disease in PNALD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Bacterial translocation from overgrowth in the small intestine also may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Short bowel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholestatic liver disease is more common in patients with short bowel syndrome (SBS) than in patients who require PN for other reasons, suggesting a role for factors unique to SBS in the pathogenesis of cholestatic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/16\">",
"     16",
"    </a>",
"    ]. The following factors have been proposed, but their relative importance is uncertain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An exaggerated pro-inflammatory cytokine response [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased bacterial translocation and sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Altered gut hormone secretion and bile flow",
"     </li>",
"     <li>",
"      Nutrient deficiencies, including essential fatty acids,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      , choline, taurine, vitamin E, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of PN and extent of bowel loss are important determinants of PNALD in infants with SBS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/19\">",
"     19",
"    </a>",
"    ]. Infants with extensive small bowel resections (eg, residual length &le;10 percent of expected) are more likely to develop cholestasis as compared with those with less extensive bowel resections or intestinal dysmotility [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Parenteral nutrition components",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few studies suggest that specific components of PN solutions are involved in the pathogenesis of PNALD:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lipid source",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soybean lipid emulsions (eg, Intralipid&reg;) are the most common form of lipid used for PN in the United States and most other countries, and have been implicated in the pathogenesis of PNALD. These emulsions are rich in omega-6 fatty acids, which have the advantage of supplying essential fatty acids.",
"   </p>",
"   <p>",
"    However, accumulating evidence suggests that soy-based lipid emulsions may be an important contributor to the pathogenesis of PNALD. Studies in animal models showed that a soy-based lipid emulsion is associated with liver injury as compared with a fish-oil based emulsion, which is rich in omega-3 fatty acids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Moreover, studies in adults have shown that soybean lipid infusions of &gt;1",
"    <span class=\"nowrap\">",
"     gm/kg",
"    </span>",
"    are one of several risk factors for developing cholestatic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/3\">",
"     3",
"    </a>",
"    ], and studies in children show a decrease in cholestasis with lipid lowering techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/24\">",
"     24",
"    </a>",
"    ]. Finally, preliminary studies in infants demonstrate a reversal of PNALD after changing from soy-based to fish-oil-based fat emulsions. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A proposed mechanism through which soy-based lipid emulsions might cause liver injury is that excessive omega-6 fatty acids have proinflammatory effects and impair triglyceride export [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/25\">",
"     25",
"    </a>",
"    ]. Soy-based lipid emulsions also contain phytosterols (eg, stigmasterol, beta-sitosterol, and campesterol) that reduce bile secretion and may contribute to liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Amino acid dose and composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for amino acids in the pathogenesis of PNALD in humans has been suggested. In animals, amino acid infusion impairs bile secretion, and some amino acids (eg, glycine, methionine) are hepatotoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In infants, short-term amino acid infusions cause biochemical evidence of cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, photodegradation products of amino acids and other components of PN may also contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/32\">",
"     32",
"    </a>",
"    ]. One retrospective study found different rates of PNALD among infants treated with two different types of pediatric amino acid preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/33\">",
"     33",
"    </a>",
"    ]; a second smaller study did not support this conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical studies in humans have failed to confirm an association between the total dose of amino acids and PNALD. A randomized trial examined the effects of two doses of amino acid supplementation as part of PN given to premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. There was no difference in the rates of cholestasis at 28 days of life (12.5 percent in patients given the lower dose of amino acids versus 8.6 in those given a higher dose), but the study was underpowered to detect such an effect. Similarly, a retrospective study did not find a difference in the protein: nonprotein calorie ratio among infants with cholestasis as compared with those without cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even if the total dose of amino acids is not associated with PNALD, an imbalance in several conditionally essential amino acids may increase the risk. As examples, taurine deficiency, L-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"     cysteine",
"    </a>",
"    deficiency, and methionine excess have been implicated as a cause of PNALD.",
"   </p>",
"   <p>",
"    Conjugation of bile acids with taurine can reduce their conjugation with glycine, which may protect the liver since glycine-conjugated bile acids are hepatotoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Neonates have limited ability to convert methionine into taurine due to low cystathionase activity. To prevent taurine deficiency, amino acid products for neonates contain higher concentrations of taurine compared with amino acid preparations designed for adults. Thus, neonates receiving the \"adult\" product may develop taurine deficiency, which may contribute to the development of PNALD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Carbohydrate excess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although dextrose is not considered hepatotoxic, excessive carbohydrate in PN may contribute to the development of PNALD. The proposed mechanism is that excessive carbohydrates enhance insulin release, leading to upregulation of enzymes involved in fatty acid synthesis, which causes hepatic steatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Hepatic steatosis is thought to predispose to inflammation via oxidative stress from reactive oxygen species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that have been proposed to contribute to PNALD in infants are the chemical composition of the tubing used to infuse PN, toxicity from trace elements, and aluminum toxicity. The concerns about each of these factors are based on limited evidence:",
"   </p>",
"   <p>",
"    In one study, changing from an infusion system in which diethylhexylphthalate (DEHP) was used as a plasticizing agent to DEHP-free tubing was associated with a marked reduction in the incidence of cholestasis among neonates receiving PN for two or more weeks (from 50 to 18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/43\">",
"     43",
"    </a>",
"    ]. Determining whether DEHP has a causal role in the pathogenesis of PNALD will depend on whether these findings are reproduced in other care settings, as well as analysis for potential confounders.",
"   </p>",
"   <p>",
"    Because copper and manganese are primarily excreted through the biliary tract, concerns have been raised that these trace elements might accumulate in patients with cholestasis and contribute to hepatic injury",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cause neurotoxicity. Some studies and case reports document elevated serum or liver levels of copper and manganese in patients on long-term PN; there is no direct evidence that this had adverse effects in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Nonetheless, many institutions routinely reduce or eliminate trace element infusions in PN after cholestasis develops [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of dietary trace minerals\", section on 'Copper'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H41#H41\">",
"     \"Overview of dietary trace minerals\", section on 'Manganese'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aluminum toxicity can predispose to cholestasis in infants. Neonates and premature infants receiving long-term PN therapy are at the highest risk. Aluminum is found in raw materials and may become incorporated into products during the manufacturing process. In addition, aluminum can contaminate solutions as a result of leaching from glass containers during storage. Although the aluminum content of parenteral nutrition solutions has been substantially reduced during the past 30 years, several commonly used solutions that are used for parenteral nutrition, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    and phosphate salts, contain clinically significant levels of aluminum. Aluminum promotes hepatocellular uptake of transferrin, which allows aluminum to enter the hepatocyte bound to transferrin, an effect that can theoretically lead to cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no consensus to define \"safe\" levels of parenteral aluminum intake. Intakes of less than 2",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    per day were recommended by the American Society of Clinical Nutrition and American Society for Parenteral and Enteral Nutrition in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/50\">",
"     50",
"    </a>",
"    ]. In 2004, the Food and Drug Administration (FDA) recommended that parenteral aluminum exposure be limited to less than 4 to 5",
"    <span class=\"nowrap\">",
"     micrograms/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/51\">",
"     51",
"    </a>",
"    ]. However, it is often difficult to achieve exposures under these limits using currently available products, particularly for preterm infants who typically have high calcium needs. Even when the solutions with the lowest available aluminum concentrations are used, the aluminum exposure from parenteral nutrition solutions exceeds the FDA recommendation for infants and children weighing less than 50 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with PNALD typically develop jaundice and elevated levels of conjugated (direct) bilirubin about two weeks after starting parenteral nutrition (PN), but the onset may be later. The laboratory findings are not specific; in addition to conjugated bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gammaglutamyl transpeptidase (GGTP) may be mildly elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/12,54\">",
"     12,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cholestasis should be attributed to PN only after other major causes have been excluded. Common causes of transient conjugated hyperbilirubinemia in neonates include sepsis or infection. All infants with sustained conjugated hyperbilirubinemia should be evaluated for biliary obstruction (eg, biliary atresia), infection, and metabolic and genetic liver diseases that require specific therapy. Several of these disorders require urgent management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24519?source=see_link\">",
"     \"Approach to neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic changes in PNALD range from steatosis to cirrhosis. Steatosis (fatty liver without inflammation) is often the first histologic change seen on liver biopsy, and is more frequently seen in adults on PN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/55\">",
"     55",
"    </a>",
"    ]. Continued exposure to PN leads to progressive changes, including hepatocellular ballooning with steatosis, portal inflammation, canalicular and intracellular cholestasis (bile plugs), and bile duct proliferation that may mimic biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/56\">",
"     56",
"    </a>",
"    ]. The degree of fibrosis can range from minimal portal fibrosis to cirrhosis. It is important to recognize that subcapsular wedge biopsies obtained at operation can overestimate the degree of fibrosis; percutaneous needle biopsy usually provides more accurate staging of fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver disease usually is progressive as long as PN is continued, although the disease may progress more slowly if oral feeds are advanced and PN is decreased.",
"   </p>",
"   <p>",
"    The cholestasis and liver test abnormalities tend to improve after the parenteral therapy is discontinued, but may persist in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/2,57,58\">",
"     2,57,58",
"    </a>",
"    ]. As an example, among 31 infants with PNALD who were successfully weaned from PN, conjugated bilirubin normalized at a median of 13 weeks after weaning (95% CI 8-14 weeks), and alanine aminotransferase (ALT) levels normalized at a median of 35 weeks (95% CI 24-80 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/2\">",
"     2",
"    </a>",
"    ]. One year after weaning from PN, all patients had normal conjugated bilirubin, but 42 percent still had abnormal ALT.",
"   </p>",
"   <p>",
"    PNALD in patients with short bowel syndrome is a major indication for combined liver-small bowel transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/59\">",
"     59",
"    </a>",
"    ]. Several studies have assessed predictors of progressing to liver failure, transplant, or death:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants with short bowel syndrome, a conjugated bilirubin greater than 5.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (100",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      for more than two weeks with no concurrent sepsis predicted the children who would advance to end stage liver disease (94 percent sensitivity and 87 percent specificity) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of infants with short bowel syndrome, total bilirubin &gt;6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      at three to six months of age predicted a 36 percent probability of developing liver failure. The combination of total bilirubin &gt;11.7",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      low platelets (&lt;168 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        3",
"       </sup>",
"       /microL)",
"      </span>",
"      and albumin &lt;3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      predicted more than 80 percent probability of liver failure [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among infants who developed PNALD in a neonatal intensive care unit, and had conjugated bilirubin &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      before two months of age, 17 percent died or went on to liver transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/62\">",
"       62",
"      </a>",
"      ]. Among those with a maximum conjugated bilirubin &gt;10",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      38 percent died or went on to liver transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PN-induced portal fibrosis often occurs early in the course of PNALD and may progress rapidly, sometimes within weeks of starting PN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/56,63,64\">",
"     56,63,64",
"    </a>",
"    ]. Fibrotic changes are common even after cholestasis has resolved. As an example, in a study of 66 children with SBS and a history of PNALD who underwent liver biopsy, nearly 90 percent had some degree of fibrosis. Even among the children in whom serum bilirubin had normalized, 55 percent of biopsies revealed some fibrosis. Furthermore, three of the eight patients with cirrhosis did not have biochemical evidence of cholestasis at the time of the biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Enteral feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important step in management of PNALD is to promote enteral feedings to reduce the dependence upon parenteral nutrition.",
"   </p>",
"   <p>",
"    Enteral feeding exposes the gastrointestinal tract to nutrient and hormonal stimuli, which are not present when the bowel is kept empty [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/66\">",
"     66",
"    </a>",
"    ]. Luminal substrates and intraluminal nutrients are essential for development of intestinal adaptation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/67\">",
"     67",
"    </a>",
"    ]. Even with minimal enteral nutrition (ie, trophic feeds), human intestinal epithelial cell growth, brush-border enzyme activity, and motility are enhanced [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these reasons, we recommend initiation of feeding early in the postoperative period. In patients who cannot tolerate even trophic feedings, nonnutritive sucking should be encouraged, as it facilitates the development of sucking behavior, and may improve tolerance to enteral feedings and assist in the transition from tube to bottle feedings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/69\">",
"     69",
"    </a>",
"    ]. Continuous feeds are often better tolerated than bolus feeds, and may hasten weaning from parenteral nutrition.",
"   </p>",
"   <p>",
"    In premature infants with mild cholestasis, liver dysfunction usually improves after discontinuation of the PN. In infants who have undergone bowel resection, cholestasis takes longer to resolve, perhaps because enteral feeding often is poorly tolerated. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Clinical course'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Infants with short bowel syndrome are at particularly high risk for developing significant liver disease, and progressive advancing of feeds and weaning of the PN solution is the most important step to prevent or attenuate the liver disease. With careful management, many children can be weaned from PN before their native liver becomes irreversibly damaged, thus avoiding the substantial short- and long-term risks associated with transplantation procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/70\">",
"     70",
"    </a>",
"    ]. Clinical approaches to optimize this progression are discussed in detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26778?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of the short bowel syndrome in children\", section on 'Enteral feeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Parenteral nutrition composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of studies have implicated the macronutrient composition of PN in the pathogenesis of PNALD. Excess total energy, as well as excessive contributions from individual macronutrients (carbohydrates, protein, and fats) have all been associated with increased risks for hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/31,42,71,72\">",
"     31,42,71,72",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Parenteral nutrition components'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As a result, it is important to prescribe PN within recommended ranges for each macronutrient, as appropriate to the age and nutritional needs of each infant. Premature infants have especially high needs for energy and protein, as discussed in a separate topic review. Nonetheless, PN should be adjusted to provide the minimum level of total energy and macronutrients required for adequate growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27434?source=see_link\">",
"     \"Parenteral nutrition in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although multiple lines of evidence point to macronutrient excess as a risk factor for cholestasis, no specific macronutrient component has been consistently identified as a causal factor. As an example, one retrospective study found no correlation between cholestasis and the daily dose of protein, glucose, and lipid calories in the PN infusates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/73\">",
"     73",
"    </a>",
"    ]. However, the duration of PN was associated with development of cholestasis, as shown in multiple other studies.",
"   </p>",
"   <p>",
"    Due to accumulating concerns that certain lipid emulsions may be an important contributor to the pathogenesis of PNALD, we limit the lipid dose to 1",
"    <span class=\"nowrap\">",
"     g/kg/day",
"    </span>",
"    upon the initiation of PN if a prolonged PN course is anticipated (ie, &gt;21 days), provided that adequate calories for growth can be provided through other PN components [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Lipid source'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prevention of sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent episodes of sepsis are an important risk factor for PNALD, and sepsis is one of the leading causes of death in patients with advanced PNALD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/13\">",
"     13",
"    </a>",
"    ]. The risk for sepsis may be attributed to the risk for catheter-related infection in patients on PN, and to bacterial translocation as a result of bacterial overgrowth in patients who are not enterally fed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/74\">",
"     74",
"    </a>",
"    ]. The effects of sepsis on the liver may be amplified by the exaggerated inflammatory response in patients with short bowel syndrome. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Short bowel syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, prevention of catheter-related sepsis through strict sterile technique, and prompt management of septic events are important steps in the management of PNALD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic and ethanol locks may be helpful in treating catheter-related sepsis. They have also been used to prevent recurrent infections in patients on chronic PN [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/75-78\">",
"       75-78",
"      </a>",
"      ]. Typically, the use of ethanol locks has been limited to infants over three months of age and weighing more than 5 kg [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/79\">",
"       79",
"      </a>",
"      ]. An advantage of ethanol as compared with antibiotic locks includes an absence of resistance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of intravascular catheter-related infections\", section on 'Antibiotic lock therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When catheter-related or other infections are suspected, they should be identified and treated promptly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"       \"Diagnosis of intravascular catheter-related infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link\">",
"       \"Treatment of intravascular catheter-related infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rotating, short courses of antibiotics have been suggested as a means of reducing bacterial overgrowth and, thus, reducing the risk of sepsis. Institutions employing this strategy have reported reductions in rates of PNALD, but the reports are unable to separate the effects of this intervention from other measures used simultaneously to manage PNALD [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/59,80,81\">",
"       59,80,81",
"      </a>",
"      ]. For this purpose,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       metronidazole",
"      </a>",
"      is most commonly used, given its broad anaerobe coverage and its own inherent anti-inflammatory properties [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/82,83\">",
"       82,83",
"      </a>",
"      ]. Some institutional protocols have alternated metronidazole with enteral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"       kanamycin",
"      </a>",
"      , with or without one or more weeks off of antibiotics between courses [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/80,81\">",
"       80,81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High-dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      , used for its prokinetic effects, appeared to provide some protection against the development of PNALD in a randomized trial in very low birth weight infants [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/84\">",
"       84",
"      </a>",
"      ]. Because the use of erythromycin has been associated with substantially increased risks of pyloric stenosis (particularly during the first two weeks of life), further evaluation of the potential benefits and risks of this treatment will be necessary before it can be recommended as a prophylactic measure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=see_link\">",
"       \"Infantile hypertrophic pyloric stenosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ursodiol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=see_link\">",
"     Ursodiol",
"    </a>",
"    (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    ) (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) appeared to be effective in both a pilot study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/85\">",
"     85",
"    </a>",
"    ] and retrospective reports [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. A systematic review confirmed that administration of ursodeoxycholic acid (10 to 30",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    generally improved biochemical parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/88\">",
"     88",
"    </a>",
"    ]. However, long-term efficacy of this drug has not been established, and larger controlled studies are needed to determine its clinical effectiveness in this disease process. Of note, some preparations of ursodiol include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    , an inert ingredient which can exacerbate diarrhea in patients with short bowel syndrome.",
"   </p>",
"   <p>",
"    Based on this limited evidence, we do a trial of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=see_link\">",
"     ursodiol",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg/dose",
"    </span>",
"    twice or three times daily) in infants with PNALD who are able to tolerate some enteral intake [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/47\">",
"     47",
"    </a>",
"    ]. If conjugated bilirubin improves but serum aminotransferase activity remains elevated, we continue ursodiol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Fish oil-based fat emulsions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because soybean fat emulsions (which have a high content of omega-6 fatty acids) have been implicated in the pathogenesis of PNALD, a few studies have investigated the effects of lipid emulsions based on fish oil (which is rich in omega-3 fatty acids). Fish oil-based fat emulsions are proposed to reduce hepatic triglyceride synthesis and inflammation, as discussed above. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Lipid source'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Evidence from several nonrandomized trials suggest that changing from soy-based to fish oil-based lipid emulsions may be effective in treating PNALD, as detailed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small, nonrandomized studies in infants with short bowel syndrome suggest that PNALD can be reversed by using fish oil-based fat emulsions, which are rich in omega-3 fatty acids, instead of or in addition to the standard soybean oil emulsion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/47,89-93\">",
"     47,89-93",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 79 infants who developed PNALD while on a soy-based lipid emulsion (Intralipid&reg;), improvements in cholestasis and lipid profile were seen after switching to a fish oil-based lipid emulsion (Omegaven&reg;, 1",
"      <span class=\"nowrap\">",
"       gram/kg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/94\">",
"       94",
"      </a>",
"      ]. After switching to the fish oil-based lipid emulsion, median direct bilirubin concentrations fell from 5.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      to 0.2",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      with a median 18 weeks of follow up. Many of the subjects had a gradual increase in enteral intake during the same time period, which could explain the observed improvements. The patients&rsquo; lipid profiles also improved, and there was no evidence of essential fatty acid deficiency (triene:tetraene ratio 0.028, range 0.019 to 0.042). Histologic outcomes were not reported, so it is unclear if there was an associated improvement in fibrosis.",
"     </li>",
"     <li>",
"      In a group of 12 infants with short bowel syndrome and severe PNALD (median conjugated bilirubin 8",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      treatment with the fish-oil based emulsion led to complete and sustained remission in nine (75 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/91\">",
"       91",
"      </a>",
"      ]. In this series, the soy-based emulsion was continued after the fish oil-based emulsion was added (1",
"      <span class=\"nowrap\">",
"       gram/kg/day",
"      </span>",
"      of each), because of theoretical concerns about the possibility of causing essential fatty acid deficiency if only fish oil sources were used. After switching to the combined lipid infusion, four patients had improvement of cholestasis. Eight patients did not improve, prompting their providers to discontinue the soybean lipid emulsion in favor of fish oil monotherapy.",
"     </li>",
"     <li>",
"      A report of two cases included liver biopsies before and after switching from a soy-based to fish oil-based lipid emulsion [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/95\">",
"       95",
"      </a>",
"      ]. In both cases there was marked improvement in portal tract inflammation, which coincided with improvements in conjugated bilirubin and other biochemical markers of liver disease. However, liver fibrosis persisted, and may even have progressed during treatment. In comparison, in a case series of six patients, published in abstract form, fibrosis resolved or was stable after switching to a fish oil-based lipid emulsion [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/96\">",
"       96",
"      </a>",
"      ]. Any meaningful conclusions about histological outcomes will require larger studies with more precisely timed biopsies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, it is possible that reduction in total lipid dose contributed to the improvement observed in these studies. This possibility is supported by a prospective study of 31 neonates with PNALD, in which the dose of lipid was markedly reduced to 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    TWICE WEEKLY (a dose equivalent to 0.14",
"    <span class=\"nowrap\">",
"     g/kg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/97\">",
"     97",
"    </a>",
"    ]. In comparison to historical controls receiving 3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day of intravenous lipids, infants receiving the low fat regimens experienced a significant decline in total bilirubin levels compared with controls. Resolution of PNALD (defined as direct bilirubin &lt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    was achieved in 42 percent of infants on the low fat regimen compared with 10 percent among matched historical controls. Comparison of growth in the two groups was similar. Mild essential fatty acid deficiency was detected in 8 of 31 infants and was reversed with additional days of lipid infusion. In contrast, other studies have not shown prevention or delay of onset of PNALD using lower lipid strategies. One observational study that included 61 neonates found no difference in incidence of cholestasis or in time to cholestasis among neonates receiving 1",
"    <span class=\"nowrap\">",
"     g/kg/day",
"    </span>",
"    of a soybean-based lipid emulsion, as compared with those receiving 2 to 3",
"    <span class=\"nowrap\">",
"     grams/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/98\">",
"     98",
"    </a>",
"    ]. Both of these studies are limited by their relatively small size and observational nature. They support the notion that soy-based lipid emulsion may contribute to PNALD, but they are not sufficient to establish a threshold of soy-based lipid emulsion that consistently reverses or prevents PNALD and that avoids essential fatty acid deficiency.",
"   </p>",
"   <p>",
"    These studies do not establish the optimal quantity of fish oil infusion, and whether a source of omega-6 fatty acids should be included (as it was in one of the studies cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/91\">",
"     91",
"    </a>",
"    ]). In addition, it is unclear whether this approach is helpful for infants or children with PNALD but without short bowel syndrome (eg, premature infants who are PN-dependent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a minimal risk for essential fatty acid deficiency (EFAD) if 1",
"    <span class=\"nowrap\">",
"     gram/kg/day",
"    </span>",
"    of fish oil is used [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/47,92,94\">",
"     47,92,94",
"    </a>",
"    ]. Similar results were seen in study of ten infants who were receiving no enteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/99\">",
"     99",
"    </a>",
"    ]. However, the risk for EFAD might increase if lower doses of lipids are given. &nbsp;",
"   </p>",
"   <p>",
"    EFAD is also a risk when transitioning from PN to full enteral feedings. Given that patients with intestinal failure are prone to fat malabsorption, careful monitoring is imperative. In some cases, the use of pancreatic enzymes may be warranted to facilitate the transition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38983?source=see_link&amp;anchor=H2#H2\">",
"     \"Micronutrient deficiencies associated with malnutrition in children\", section on 'Essential fatty acid deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Implementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For infants with marked progressive PNALD despite optimization of the general measures described above who are predicted to require parenteral nutrition for at least an additional 30 days, we usually change the lipid source to fish oil (Omegaven&reg;), at a dose of 1",
"    <span class=\"nowrap\">",
"     gram/kg/day.",
"    </span>",
"    As discussed above, this is based on evidence from a few nonrandomized trials.",
"   </p>",
"   <p>",
"    Because of hypothetical risks for essential fatty acid deficiency in infants maintained on fish oil as the exclusive source of lipids, we routinely monitor the triene:tetraene ratio at least once monthly. Triene:tetraene ratios &gt;0.2 suggest essential fatty acid deficiency. In our practice, we do not mix fish oil lipid emulsions with conventional soybean oil emulsions when treating PNALD. Monotherapy with a fish oil-based lipid emulsion is supported by a position paper by the American Society for Parenteral and Enteral Nutrition (ASPEN) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, the use of fish oil-based lipid emulsions in the United States requires compassionate use approval from the United States Food and Drug Administration (FDA) on a case-by-case basis. Practitioners in the United States wishing to consider this therapy should refer to the OLEY Foundation's website (",
"    <a class=\"external\" href=\"file://oley.org/\">",
"     OLEY.org",
"    </a>",
"    ) for current ordering and prescribing information for Omegaven&reg; (Fresenius Kabi). Omegaven&reg; is available without special approvals in many countries outside of the United States. Other fish oil-containing lipid emulsions are available outside the United States (eg, SMOFlipid&reg;, Fresenius Kabi; and Lipoplus, B.Braun), and investigations are in progress to determine whether they are useful for the prevention or treatment of PNALD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]. In a single center randomized trial, 28 children receiving home parenteral nutrition received either an emulsion composed of fish oil and other oils (SMOFlipid&reg;) or a standard soy-based lipid emulsion for one month [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/102\">",
"     102",
"    </a>",
"    ]. Patients received the assigned lipid emulsion four to five times per week at a goal dose of 2",
"    <span class=\"nowrap\">",
"     g/kg/day.",
"    </span>",
"    After 29 days, the children receiving the fish oil-containing emulsion had a statistically significant reduction in total bilirubin concentration (mean change from baseline, -1.5 &plusmn; 2.4",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    as compared with those receiving the soy-based lipid emulsion (2.3 &plusmn; 3.5",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Despite these results, a systematic review of PNALD by the American Pediatric Surgical Association concluded that there is still insufficient evidence to support the use of SMOFlipid&reg; as the preferred lipid source in children with long-term PN dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/47\">",
"     47",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Disclosure: One of the authors of this topic review (KG) is named in an institutional application for a use patent for Omegaven&reg; and other fish oil-based lipid emulsions for the treatment of PNALD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Except for these preliminary results of omega-3 fatty acids and the optimization of PN and achievement of full enteral feedings, no specific therapy to either prevent or reduce the severity of PNALD has been found. Strategies with some merit include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cholecystokinin-octapeptide, a gastrointestinal hormone that induces gallbladder contraction and increases intrahepatic bile flow, showed initial promise [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/104\">",
"       104",
"      </a>",
"      ] but was not effective in either preventing or reducing the severity of cholestasis in a controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"       Cysteine",
"      </a>",
"      supplementation has been suggested to counteract the effects of excessive methionine, which is thought to be a mechanism of oxidative hepatotoxicity in PNALD, as discussed above. In a small case series, N-acetyl cysteine was given as a source of cysteine to two infants and one older child with PNALD [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/106\">",
"       106",
"      </a>",
"      ]. Treatment for 3 to 18 months with N-acetyl cysteine was associated with apparent improvement in cholestatic liver disease, as suggested by reductions in serum bilirubin, aminotransferase activities and ferritin in all three patients. Although these results are promising, considerably more study is required before this can be generally recommended as a treatment for PNALD.",
"     </li>",
"     <li>",
"      Antioxidant therapy has been suggested as a therapeutic option in treating PNALD. This approach is based on the hypothesis that oxidative stress acts as a second \"hit\" leading to the cell injury and death in the setting of hepatic steatosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Carbohydrate excess'",
"      </a>",
"      above.) Although treatment with vitamin E appears to attenuate hepatic injury in animal models, human data is still lacking. Proponents of this hypothesis suggest that the addition of alpha tocopherol to parenteral lipid emulsions, either at the time of manufacturer or exogenously, can minimize risks for PNALD [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/67,107\">",
"       67,107",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all infants requiring parenteral nutrition, we make concerted efforts to maximize enteral feedings and progressively wean off of parenteral nutrition as soon as possible, while preserving nutritional status. This is especially important in infants with short bowel syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26778?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of the short bowel syndrome in children\", section on 'Enteral feeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients unable to be weaned from PN, the following interventions are used in an effort to prevent PNALD. We often use multiple approaches concurrently:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review the nutritional history to ensure that the patient is not receiving excessive energy from carbohydrate or fats. For critically ill children who are fluid restricted, medications may be diluted in dextrose-containing fluids to deliver adequate calories. As fluids are liberalized, reducing the carbohydrate concentration of the PN may be necessary.",
"     </li>",
"     <li>",
"      Review the medication list for potentially hepatotoxic medications that could be contributing to the development of liver disease. As an example, drugs such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/1/33815?source=see_link\">",
"       ranitidine",
"      </a>",
"      (which is often added directly to PN) can cause elevations of serum aminotransferase levels. Cholestasis may be associated with certain antibiotics, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      , and penicillins (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link\">",
"       \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cycle the PN as soon as the child is able to tolerate it. There is some evidence that this limits PN hepatotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/108\">",
"       108",
"      </a>",
"      ]. Cycling of PN is not generally tolerated in neonates because of hypoglycemia, and is not usually attempted before 44 to 48 weeks postmenstrual age.",
"     </li>",
"     <li>",
"      If a prolonged PN course is anticipated (ie, &gt;21 days), we limit the lipid dose to 1",
"      <span class=\"nowrap\">",
"       g/kg/day",
"      </span>",
"      upon the initiation of PN, if adequate calories for growth can be provided through other PN components. This approach is consistent with suggestions from the American Society for Parenteral and Enteral Nutrition (ASPEN) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/18/18730/abstract/100\">",
"       100",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Parenteral nutrition composition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Protect the PN solution from ambient light using UV resistant covers to minimize photooxidation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Amino acid dose and composition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimize the amount of aluminum contamination whenever possible. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Other causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Employ an ethanol lock in patients with a history of catheter-related sepsis. We typically use 70 percent ethanol three times per week. The dose is tailored to the volume of the patient's catheter; care is taken not to inject the ethanol after a minimum dwell time. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prevention of sepsis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of intravascular catheter-related infections\", section on 'Antibiotic lock therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parenteral nutrition-associated liver disease (PNALD) is defined as an elevated serum conjugated bilirubin &ge;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (34.2",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      occurring in the setting of parenteral nutrition, if other specific causes of liver injury are excluded. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for developing PNALD are young age, short bowel syndrome, intercurrent infections, lack of enteral feedings, and duration of parenteral nutrition. Emerging evidence suggests that the soybean oils that are used in conventional intravenous lipid emulsions may contribute to the risk for developing PNALD. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features of PNALD are conjugated hyperbilirubinemia, with mild or moderate elevations of serum AST, ALT, and GGTP. The liver disease is usually progressive unless parenteral therapy can be discontinued. End-stage liver disease develops in a substantial portion of infants requiring sustained parenteral nutrition, and leads to liver transplantation or death. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all infants requiring parenteral nutrition, the risk for PNALD can be reduced by adjusting PN to provide the minimum level of total energy and macronutrients required for adequate growth, transitioning to enteral feeds as rapidly as is tolerated, cycling PN when possible, and preventing and promptly treating catheter-related sepsis. Techniques that are useful for maximizing enteral feeds in infants with short bowel syndrome are discussed separately. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Enteral feeding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26778?source=see_link\">",
"       \"Management of the short bowel syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For infants requiring parenteral nutrition for more than 30 days, we suggest administering lipids at no more than 1",
"      <span class=\"nowrap\">",
"       gram/kg/day",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This suggestion assumes that adequate calories for growth can be safely provided through other PN components. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Parenteral nutrition composition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of PNALD has not been established, and may continue to evolve with improvements in understanding the pathogenesis of the disorder. Recognizing that the evidence supporting any of the interventions described above is limited, we take the following approach in our practice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants who develop cholestasis (conjugated bilirubin &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      we ensure that each of the general measures discussed above are in place, particularly reduction of the lipid dose to no more than 1",
"      <span class=\"nowrap\">",
"       gm/kg/day,",
"      </span>",
"      and adjusting PN to provide the minimum level of total energy and macronutrients required for adequate growth.",
"     </li>",
"     <li>",
"      For infants who develop cholestasis and are able to tolerate some enteral intake, we generally treat with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=see_link\">",
"       ursodiol",
"      </a>",
"      (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      ), 10",
"      <span class=\"nowrap\">",
"       mg/kg/dose",
"      </span>",
"      given twice or three times daily. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Ursodiol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the direct bilirubin is &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      for 30 days despite reduction of lipid dose and other preventative measures, we reduce the dose of the trace elements in the PN by 50 percent. We maintain the prior level of zinc supplementation through the use of supplements. Because the reduced dose of trace elements might cause copper deficiency, we monitor copper and ceruloplasmin periodically. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Other causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For infants with severe and progressive PNALD despite the above measures, we suggest treating with a fish-oil source of lipids rather than soybean oil source (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If fish oil is used as the exclusive source of lipids, at least 1",
"      <span class=\"nowrap\">",
"       gram/kg/day",
"      </span>",
"      should be given, and the triene:tetraene ratio should be monitored to detect essential fatty acid deficiency. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Fish oil-based fat emulsions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because the use of fish oil-based lipid emulsions for parenteral nutrition is still an investigational therapy in the United States, its implementation requires compassionate use protocols. These products are available and approved for this use in many countries outside of the United States. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Implementation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/1\">",
"      Kelly DA. Liver complications of pediatric parenteral nutrition--epidemiology. Nutrition 1998; 14:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/2\">",
"      Yang CF, Lee M, Valim C, et al. Persistent alanine aminotransferase elevations in children with parenteral nutrition-associated liver disease. J Pediatr Surg 2009; 44:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/3\">",
"      Cavicchi M, Beau P, Crenn P, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000; 132:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/4\">",
"      Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology 2006; 130:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/5\">",
"      Cooper A, Floyd TF, Ross AJ 3rd, et al. Morbidity and mortality of short-bowel syndrome acquired in infancy: an update. J Pediatr Surg 1984; 19:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/6\">",
"      Christensen RD, Henry E, Wiedmeier SE, et al. Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease. J Perinatol 2007; 27:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/7\">",
"      Moss RL, Amii LA. New approaches to understanding the etiology and treatment of total parenteral nutrition-associated cholestasis. Semin Pediatr Surg 1999; 8:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/8\">",
"      Pereira GR, Sherman MS, DiGiacomo J, et al. Hyperalimentation-induced cholestasis. Increased incidence and severity in premature infants. Am J Dis Child 1981; 135:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/9\">",
"      Robinson DT, Ehrenkranz RA. Parenteral nutrition-associated cholestasis in small for gestational age infants. J Pediatr 2008; 152:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/10\">",
"      Beale EF, Nelson RM, Bucciarelli RL, et al. Intrahepatic cholestasis associated with parenteral nutrition in premature infants. Pediatrics 1979; 64:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/11\">",
"      Beath SV, Davies P, Papadopoulou A, et al. Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors. J Pediatr Surg 1996; 31:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/12\">",
"      Teitelbaum DH. Parenteral nutrition-associated cholestasis. Curr Opin Pediatr 1997; 9:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/13\">",
"      Sondheimer JM, Asturias E, Cadnapaphornchai M. Infection and cholestasis in neonates with intestinal resection and long-term parenteral nutrition. J Pediatr Gastroenterol Nutr 1998; 27:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/14\">",
"      Wolf A, Pohlandt F. Bacterial infection: the main cause of acute cholestasis in newborn infants receiving short-term parenteral nutrition. J Pediatr Gastroenterol Nutr 1989; 8:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/15\">",
"      Cole CR, Frem JC, Schmotzer B, et al. The rate of bloodstream infection is high in infants with short bowel syndrome: relationship with small bowel bacterial overgrowth, enteral feeding, and inflammatory and immune responses. J Pediatr 2010; 156:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/16\">",
"      Diamanti A, Basso MS, Castro M, et al. Irreversible intestinal failure: prevalence and prognostic factors. J Pediatr Gastroenterol Nutr 2008; 47:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/17\">",
"      Aprahamian CJ, Chen M, Yang Y, et al. Two-hit rat model of short bowel syndrome and sepsis: independent of total parenteral nutrition, short bowel syndrome is proinflammatory and injurious to the liver. J Pediatr Surg 2007; 42:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/18\">",
"      Slicker J, Vermilyea S. Pediatric parenteral nutrition: putting the microscope on macronutrients and micronutrients. Nutr Clin Pract 2009; 24:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/19\">",
"      Duro D, Mitchell PD, Kalish LA, et al. Risk factors for parenteral nutrition&ndash;associated liver disease following surgical therapy for necrotizing enterocolitis: A Glaser Pediatric Research Network Study [corrected]. J Pediatr Gastroenterol Nutr 2011; 52:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/20\">",
"      Spencer AU, Neaga A, West B, et al. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg 2005; 242:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/21\">",
"      Pakarinen MP, Koivusalo AI, Rintala RJ. Outcomes of intestinal failure--a comparison between children with short bowel and dysmotile intestine. J Pediatr Surg 2009; 44:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/22\">",
"      Alwayn IP, Gura K, Nos&eacute; V, et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res 2005; 57:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/23\">",
"      Van Aerde JE, Duerksen DR, Gramlich L, et al. Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. Pediatr Res 1999; 45:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/24\">",
"      Colomb V, Jobert-Giraud A, Lacaille F, et al. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J Parenter Enteral Nutr 2000; 24:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/25\">",
"      Gawecka A, Michalkiewicz J, Kornacka MK, et al. Immunologic properties differ in preterm infants fed olive oil vs soy-based lipid emulsions during parenteral nutrition. JPEN J Parenter Enteral Nutr 2008; 32:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/26\">",
"      Clayton PT, Whitfield P, Iyer K. The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition. Nutrition 1998; 14:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/27\">",
"      Carter BA, Taylor OA, Prendergast DR, et al. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res 2007; 62:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/28\">",
"      Xu Z, Harvey KA, Pavlina T, et al. Steroidal compounds in commercial parenteral lipid emulsions. Nutrients 2012; 4:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/29\">",
"      Shattuck KE, Grinnell CD, Rassin DK. Amino acid infusions induce reversible, dose-related decreases in bile flow in the isolated rat liver. JPEN J Parenter Enteral Nutr 1993; 17:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/30\">",
"      Moss RL, Haynes AL, Pastuszyn A, Glew RH. Methionine infusion reproduces liver injury of parenteral nutrition cholestasis. Pediatr Res 1999; 45:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/31\">",
"      Black DD, Suttle EA, Whitington PF, et al. The effect of short-term total parenteral nutrition on hepatic function in the human neonate: a prospective randomized study demonstrating alteration of hepatic canalicular function. J Pediatr 1981; 99:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/32\">",
"      Bhatia J, Moslen MT, Haque AK, et al. Total parenteral nutrition-associated alterations in hepatobiliary function and histology in rats: is light exposure a clue? Pediatr Res 1993; 33:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/33\">",
"      Wright K, Ernst KD, Gaylord MS, et al. Increased incidence of parenteral nutrition-associated cholestasis with aminosyn PF compared to trophamine. J Perinatol 2003; 23:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/34\">",
"      Forchielli ML, Gura KM, Sandler R, Lo C. Aminosyn PF or trophamine: which provides more protection from cholestasis associated with total parenteral nutrition? J Pediatr Gastroenterol Nutr 1995; 21:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/35\">",
"      Steinbach M, Clark RH, Kelleher AS, et al. Demographic and nutritional factors associated with prolonged cholestatic jaundice in the premature infant. J Perinatol 2008; 28:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/36\">",
"      Clark RH, Chace DH, Spitzer AR, Pediatrix Amino Acid Study Group. Effects of two different doses of amino acid supplementation on growth and blood amino acid levels in premature neonates admitted to the neonatal intensive care unit: a randomized, controlled trial. Pediatrics 2007; 120:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/37\">",
"      Blau J, Sridhar S, Mathieson S, Chawla A. Effects of protein/nonprotein caloric intake on parenteral nutrition associated cholestasis in premature infants weighing 600-1000 grams. JPEN J Parenter Enteral Nutr 2007; 31:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/38\">",
"      Zaman N, Tam YK, Jewell LD, Coutts RT. Effects of taurine supplementation in parenteral nutrition-associated hepatosteatosis and lidocaine metabolism. A study using isolated rat liver perfusion. Drug Metab Dispos 1996; 24:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/39\">",
"      Guertin F, Roy CC, Lepage G, et al. Effect of taurine on total parenteral nutrition-associated cholestasis. JPEN J Parenter Enteral Nutr 1991; 15:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/40\">",
"      Dahlstr&ouml;m KA, Ament ME, Laidlaw SA, Kopple JD. Plasma amino acid concentrations in children receiving long-term parenteral nutrition. J Pediatr Gastroenterol Nutr 1988; 7:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/41\">",
"      Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002; 60:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/42\">",
"      Li S, Nussbaum MS, Teague D, et al. Increasing dextrose concentrations in total parenteral nutrition (TPN) causes alterations in hepatic morphology and plasma levels of insulin and glucagon in rats. J Surg Res 1988; 44:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/43\">",
"      von Rettberg H, Hannman T, Subotic U, et al. Use of di(2-ethylhexyl)phthalate-containing infusion systems increases the risk for cholestasis. Pediatrics 2009; 124:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/44\">",
"      McMillan NB, Mulroy C, MacKay MW, et al. Correlation of cholestasis with serum copper and whole-blood manganese levels in pediatric patients. Nutr Clin Pract 2008; 23:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/45\">",
"      Fell JM, Reynolds AP, Meadows N, et al. Manganese toxicity in children receiving long-term parenteral nutrition. Lancet 1996; 347:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/46\">",
"      Blaszyk H, Wild PJ, Oliveira A, et al. Hepatic copper in patients receiving long-term total parenteral nutrition. J Clin Gastroenterol 2005; 39:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/47\">",
"      Rangel SJ, Calkins CM, Cowles RA, et al. Parenteral nutrition-associated cholestasis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg 2012; 47:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/48\">",
"      Greene HL, Hambidge KM, Schanler R, Tsang RC. Guidelines for the use of vitamins, trace elements, calcium, magnesium, and phosphorus in infants and children receiving total parenteral nutrition: report of the Subcommittee on Pediatric Parenteral Nutrient Requirements from the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition. Am J Clin Nutr 1988; 48:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/49\">",
"      Klein GL, Goldblum RM, Moslen MT, et al. Increased biliary transferrin excretion following parenteral aluminium administration to rats. Pharmacol Toxicol 1993; 72:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/50\">",
"      Parenteral drug products containing aluminum as an ingredient or a contaminant: response to Food and Drug Administration notice of intent and request for information. ASCN/A.S.P.E.N. Working Group on Standards for Aluminum Content of Parenteral Nutrition Solutions. JPEN J Parenter Enteral Nutr 1991; 15:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/51\">",
"      Food and Drug Administration. Aluminium in large and small volume parenterals used in total parenteral nutrition. Fed Regist 2000; 65:4103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/52\">",
"      Poole RL, Hintz SR, Mackenzie NI, Kerner JA Jr. Aluminum exposure from pediatric parenteral nutrition: meeting the new FDA regulation. JPEN J Parenter Enteral Nutr 2008; 32:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/53\">",
"      Smith BS, Kothari H, Hayes BD, et al. Effect of additive selection on calculated aluminum content of parenteral nutrient solutions. Am J Health Syst Pharm 2007; 64:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/54\">",
"      Hofmann AF. Defective biliary secretion during total parenteral nutrition: probable mechanisms and possible solutions. J Pediatr Gastroenterol Nutr 1995; 20:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/55\">",
"      Nightingale JM. Hepatobiliary, renal and bone complications of intestinal failure. Best Pract Res Clin Gastroenterol 2003; 17:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/56\">",
"      Zambrano E, El-Hennawy M, Ehrenkranz RA, et al. Total parenteral nutrition induced liver pathology: an autopsy series of 24 newborn cases. Pediatr Dev Pathol 2004; 7:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/57\">",
"      Forchielli ML, Walker WA. Nutritional factors contributing to the development of cholestasis during total parenteral nutrition. Adv Pediatr 2003; 50:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/58\">",
"      Javid PJ, Collier S, Richardson D, et al. The role of enteral nutrition in the reversal of parenteral nutrition-associated liver dysfunction in infants. J Pediatr Surg 2005; 40:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/59\">",
"      Vanderhoof JA, Langnas AN. Short-bowel syndrome in children and adults. Gastroenterology 1997; 113:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/60\">",
"      Nasr A, Avitzur Y, Ng VL, et al. The use of conjugated hyperbilirubinemia greater than 100 micromol/L as an indicator of irreversible liver disease in infants with short bowel syndrome. J Pediatr Surg 2007; 42:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/61\">",
"      Kaufman SS, Pehlivanova M, Fennelly EM, et al. Predicting liver failure in parenteral nutrition-dependent short bowel syndrome of infancy. J Pediatr 2010; 156:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/62\">",
"      Willis TC, Carter BA, Rogers SP, et al. High rates of mortality and morbidity occur in infants with parenteral nutrition-associated cholestasis. JPEN J Parenter Enteral Nutr 2010; 34:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/63\">",
"      Moss RL, Das JB, Raffensperger JG. Total parenteral nutrition-associated cholestasis: clinical and histopathologic correlation. J Pediatr Surg 1993; 28:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/64\">",
"      Mullick FG, Moran CA, Ishak KG. Total parenteral nutrition: a histopathologic analysis of the liver changes in 20 children. Mod Pathol 1994; 7:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/65\">",
"      Fitzgibbons SC, Jones BA, Hull MA, et al. Relationship between biopsy-proven parenteralnutrition-associated liver fibrosis and biochemical cholestasis in children with short bowel syndrome. J Pediatr Surg 2010; 45:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/66\">",
"      Jeejeebhoy KN. Management of short bowel syndrome: avoidance of total parenteral nutrition. Gastroenterology 2006; 130:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/67\">",
"      Goulet O. Short bowel syndrome in pediatric patients. Nutrition 1998; 14:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/68\">",
"      Perdikis DA, Basson MD. Basal nutrition promotes human intestinal epithelial (Caco-2) proliferation, brush border enzyme activity, and motility. Crit Care Med 1997; 25:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/69\">",
"      Pimenta HP, Moreira ME, Rocha AD, et al. Effects of non-nutritive sucking and oral stimulation on breastfeeding rates for preterm, low birth weight infants: a randomized clinical trial. J Pediatr (Rio J) 2008; 84:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/70\">",
"      Torres C, Sudan D, Vanderhoof J, et al. Role of an intestinal rehabilitation program in the treatment of advanced intestinal failure. J Pediatr Gastroenterol Nutr 2007; 45:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/71\">",
"      Komura J, Yano H, Tanaka Y, Tsuru T. Increased incidence of cholestasis during total parenteral nutrition in children--factors affecting stone formation. Kurume Med J 1993; 40:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/72\">",
"      Messing B, Colombel JF, Heresbach D, et al. Chronic cholestasis and macronutrient excess in patients treated with prolonged parenteral nutrition. Nutrition 1992; 8:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/73\">",
"      Drongowski RA, Coran AG. An analysis of factors contributing to the development of total parenteral nutrition-induced cholestasis. JPEN J Parenter Enteral Nutr 1989; 13:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/74\">",
"      O'Brien DP, Nelson LA, Kemp CJ, et al. Intestinal permeability and bacterial translocation are uncoupled after small bowel resection. J Pediatr Surg 2002; 37:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/75\">",
"      Messing B, Peitra-Cohen S, Debure A, et al. Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. JPEN J Parenter Enteral Nutr 1988; 12:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/76\">",
"      Opilla MT, Kirby DF, Edmond MB. Use of ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients. JPEN J Parenter Enteral Nutr 2007; 31:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/77\">",
"      Jones BA, Hull MA, Richardson DS, et al. Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure. J Pediatr Surg 2010; 45:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/78\">",
"      Oliveira C, Nasr A, Brindle M, Wales PW. Ethanol locks to prevent catheter-related bloodstream infections in parenteral nutrition: a meta-analysis. Pediatrics 2012; 129:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/79\">",
"      Mouw E, Chessman K, Lesher A, Tagge E. Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome. J Pediatr Surg 2008; 43:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/80\">",
"      Meehan JJ, Georgeson KE. Prevention of liver failure in parenteral nutrition-dependent children with short bowel syndrome. J Pediatr Surg 1997; 32:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/81\">",
"      Sigalet D, Boctor D, Robertson M, et al. Improved outcomes in paediatric intestinal failure with aggressive prevention of liver disease. Eur J Pediatr Surg 2009; 19:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/82\">",
"      Freund HR, Muggia-Sullam M, LaFrance R, et al. A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements. J Surg Res 1985; 38:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/83\">",
"      Capron JP, Gineston JL, Herve MA, Braillon A. Metronidazole in prevention of cholestasis associated with total parenteral nutrition. Lancet 1983; 1:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/84\">",
"      Ng PC, Lee CH, Wong SP, et al. High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants. Gastroenterology 2007; 132:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/85\">",
"      Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology 1996; 111:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/86\">",
"      Levine A, Maayan A, Shamir R, et al. Parenteral nutrition-associated cholestasis in preterm neonates: evaluation of ursodeoxycholic acid treatment. J Pediatr Endocrinol Metab 1999; 12:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/87\">",
"      Chen CY, Tsao PN, Chen HL, et al. Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. J Pediatr 2004; 145:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/88\">",
"      San Luis VA, Btaiche IF. Ursodiol in patients with parenteral nutrition-associated cholestasis. Ann Pharmacother 2007; 41:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/89\">",
"      Gura KM, Duggan CP, Collier SB, et al. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics 2006; 118:e197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/90\">",
"      Gura KM, Lee S, Valim C, et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 2008; 121:e678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/91\">",
"      Diamond IR, Sterescu A, Pencharz PB, et al. Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr 2009; 48:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/92\">",
"      Puder M, Valim C, Meisel JA, et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg 2009; 250:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/93\">",
"      Premkumar MH, Carter BA, Hawthorne KM, et al. High rates of resolution of cholestasis in parenteral nutrition-associated liver disease with fish oil-based lipid emulsion monotherapy. J Pediatr 2013; 162:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/94\">",
"      Le HD, de Meijer VE, Robinson EM, et al. Parenteral fish-oil-based lipid emulsion improves fatty acid profiles and lipids in parenteral nutrition-dependent children. Am J Clin Nutr 2011; 94:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/95\">",
"      Soden JS, Lovell MA, Brown K, et al. Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure. J Pediatr 2010; 156:327.",
"     </a>",
"    </li>",
"    <li>",
"     Dimmitt RA, Leadford Al, Bartle D, et al. Impact of omega-3 fatty acids on liver function test and liver histology in children with intestinal failure associated intestinal disease. Pediatric Academic Society Boston MA April 30,2012 E-PAS2012:3830.366",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/97\">",
"      Cober MP, Killu G, Brattain A, et al. Intravenous fat emulsions reduction for patients with parenteral nutrition-associated liver disease. J Pediatr 2012; 160:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/98\">",
"      Nehra D, Fallon EM, Carlson SJ, et al. Provision of a Soy-Based Intravenous Lipid Emulsion at 1 g/kg/d Does Not Prevent Cholestasis in Neonates. JPEN J Parenter Enteral Nutr 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/99\">",
"      de Meijer VE, Le HD, Meisel JA, et al. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr 2010; 50:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/100\">",
"      Vanek VW, Seidner DL, Allen P, et al. A.S.P.E.N. position paper: Clinical role for alternative intravenous fat emulsions. Nutr Clin Pract 2012; 27:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/101\">",
"      Tomsits E, Pataki M, T&ouml;lgyesi A, et al. Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: a randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. J Pediatr Gastroenterol Nutr 2010; 51:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/102\">",
"      Goulet O, Ant&eacute;bi H, Wolf C, et al. A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: a single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr 2010; 34:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/103\">",
"      Rayyan M, Devlieger H, Jochum F, Allegaert K. Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. JPEN J Parenter Enteral Nutr 2012; 36:81S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/104\">",
"      Teitelbaum DH, Han-Markey T, Drongowski RA, et al. Use of cholecystokinin to prevent the development of parenteral nutrition-associated cholestasis. JPEN J Parenter Enteral Nutr 1997; 21:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/105\">",
"      Teitelbaum DH, Tracy TF Jr, Aouthmany MM, et al. Use of cholecystokinin-octapeptide for the prevention of parenteral nutrition-associated cholestasis. Pediatrics 2005; 115:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/106\">",
"      Mager DR, Marcon M, Wales P, Pencharz PB. Use of N-acetyl cysteine for the treatment of parenteral nutrition-induced liver disease in children receiving home parenteral nutrition. J Pediatr Gastroenterol Nutr 2008; 46:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/107\">",
"      Becvarova I, Saker KE, Swecker WS Jr, Troy GC. Peroxidative protection of parenteral admixture by D-alpha-tocopherol. Vet Ther 2005; 6:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/18/18730/abstract/108\">",
"      Jensen AR, Goldin AB, Koopmeiners JS, et al. The association of cyclic parenteral nutrition and decreased incidence of cholestatic liver disease in patients with gastroschisis. J Pediatr Surg 2009; 44:183.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5948 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18730=[""].join("\n");
var outline_f18_18_18730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immature liver function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inflammatory mediators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Short bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Parenteral nutrition components",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lipid source",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Amino acid dose and composition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Carbohydrate excess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Enteral feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Parenteral nutrition composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prevention of sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ursodiol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Fish oil-based fat emulsions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Implementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24519?source=related_link\">",
"      Approach to neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=related_link\">",
"      Causes of neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=related_link\">",
"      Chronic complications of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=related_link\">",
"      Infantile hypertrophic pyloric stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26778?source=related_link\">",
"      Management of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38983?source=related_link\">",
"      Micronutrient deficiencies associated with malnutrition in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27434?source=related_link\">",
"      Parenteral nutrition in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_18_18731="Articles containing latex";
var content_f18_18_18731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Latex content of articles used during surgery or procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Items which may contain natural rubber latex:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gloves (sterile and exam)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drains (Penrose and others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Catheters (indwelling, straight, and condom)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Items which are now usually latex free:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ambu-bag, airway masks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Catheter leg bag straps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elastic bandages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Electrode pads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endotracheal tubes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intravenous bags, ports, infusion sets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Self-adhesive bandages and adhesive tape",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suction catheters",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Chacko T, Ledford D. Peri-anesthetic anaphylaxis. Immunol Allergy Clin N Am 2007; 27:213. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18731=[""].join("\n");
var outline_f18_18_18731=null;
var title_f18_18_18732="Hx GERD child";
var content_f18_18_18732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key elements of history in child with suspected gastroesophageal reflux disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Symptoms suggesting GERD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Heartburn or abdominal pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acid brash, regurgitation, or \"wet burps\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nocturnal coughing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic sore throat",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use of antacids or acid suppressing medication",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pattern of regurgitation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Onset",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Frequency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Triggers (association with feeding, anxiety or activity)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Painful",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Forceful",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bloody",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Positional (eg, only when recumbent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Meals",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Association with specific foods",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Size of meals if preceding regurgitation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Changes in appetite, food refusal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Growth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Weight class or percentiles",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trends in weight gain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Related medical problems",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Occult or recognized constipation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prematurity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Newborn screen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Significant medical illnesses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asthma, pneumonia, chronic cough",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Family history of gastrointestinal or metabolic disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Psychosocial history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stressors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       School absences",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Separation problems",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anxiety/depression",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18732=[""].join("\n");
var outline_f18_18_18732=null;
var title_f18_18_18733="Design adjuv trastuzumab trials";
var content_f18_18_18733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Design of adjuvant trials using trastuzumab",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Trial",
"        <br/>",
"        (number of patients)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment arms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition of severe cardiotoxicity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Monitoring frequency",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         NSABP B-31",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         (n = 2030)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         AC for four cycles, paclitaxel for four cycles, then observation",
"        </p>",
"        <p>",
"         AC for four cycles, followed by paclitaxel for four cycles, with concurrent trastuzumab, continued for one year",
"        </p>",
"       </td>",
"       <td>",
"        Grade III/IV HF or cardiac death; or LVEF decrease &gt;15 points*",
"       </td>",
"       <td>",
"        MUGA three weeks, six months, and nine months after end of initial AC, and three months after last trastuzumab dose",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         HERA",
"         <sup>",
"          [2]",
"         </sup>",
"        </p>",
"        <p>",
"         (n = 5090)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Any chemotherapy regimen, then observation",
"        </p>",
"        <p>",
"         Any chemotherapy regimen, then trastuzumab for one year",
"        </p>",
"        <p>",
"         Any chemotherapy regimen, then trastuzumab for two years",
"        </p>",
"       </td>",
"       <td>",
"        Severe HF; symptomatic HF; or LVEF decrease &gt;10 points*",
"       </td>",
"       <td>",
"        LVEF (echo or MUGA) at baseline, 3, 6, 12, 18, 24, 30, 36, and 60 months",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         BCIRG-006",
"         <sup>",
"          [3]",
"         </sup>",
"        </p>",
"        <p>",
"         (n = 3222)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         AC for four cycles, docetaxel for four cycles, then observation",
"        </p>",
"        <p>",
"         AC for four cycles, followed by docetaxel for four cycles, with concurrent trastuzumab, continued for one year",
"        </p>",
"        <p>",
"         Docetaxel and carboplatin for six cycles, with concurrent trastuzumab, continued for one year",
"        </p>",
"       </td>",
"       <td>",
"        Grade III/IV HF; cardiac death; grade 3 to 4 arrhythmias; grade 3 to 4 ischemia/infarction; or LVEF decrease &gt;10 points*",
"       </td>",
"       <td>",
"        After AC, after second dose of docetaxel, at end of chemotherapy, and 3, 12, and 36 months after randomization",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         FinHer",
"         <sup>",
"          [4]",
"         </sup>",
"        </p>",
"        <p>",
"         (n = 232)",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Docetaxel (every three weeks) and vinorelbine (weekly) for three cycles, then CEF for three cycles",
"        </p>",
"        <p>",
"         Docetaxel (every three weeks) and vinorelbine (weekly) for three cycles, plus trastuzumab for nine weeks, then CEF for three cycles",
"        </p>",
"       </td>",
"       <td>",
"        Myocardial infarction; HF; or LVEF decrease &gt;15 points",
"       </td>",
"       <td>",
"        Echo or MUGA before chemotherapy, after CEF, and 12 and 36 months after chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         NCCTG N9831",
"         <sup>",
"          [5]",
"         </sup>",
"        </p>",
"        <p>",
"         (n = 3505)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         AC for four cycles, weekly paclitaxel for 12 weeks, then observation",
"        </p>",
"        <p>",
"         AC for four cycles, weekly paclitaxel for 12 weeks, with concurrent trastuzumab, continued for one year",
"        </p>",
"        <p>",
"         AC for four cycles, weekly placlitaxel for 12 weeks, followed by trastuzumab for one year",
"        </p>",
"       </td>",
"       <td>",
"        Grade III/IV HF or cardiac death; or LVEF decrease &gt;15 points*",
"       </td>",
"       <td>",
"        MUGA or echo at entry, after AC, and 6, 9, 18, and 21 months after entry",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AC: doxorubicin and cyclophosphamide; HF: heart failure; LVEF: left ventricular heart failure; MUGA: multi-gated acquisition scan; CEF: cyclophosphamide, epirubicin, and fluorouracil.",
"     <br/>",
"     * Measured from baseline.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Only patients with HER2-positive disease.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Romond EH, et al. N Engl J Med 2005; 353:1673.",
"      </li>",
"      <li>",
"       Piccart-Gebhart MJ, et al. N Engl J Med 2005; 353:1659.",
"      </li>",
"      <li>",
"       Slamon D, et al. N Engl J Med 2011; 365:1273.",
"      </li>",
"      <li>",
"       Joensuu H, et al. N Engl J Med 2006; 354:809.",
"      </li>",
"      <li>",
"       Perez A, et al. J Clin Oncol 2011; 29:4491.",
"      </li>",
"     </ol>",
"     <br/>",
"     Modified from: Bria E, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2007; Epublished; Telli ML, et al. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007; 25:3525.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18733=[""].join("\n");
var outline_f18_18_18733=null;
var title_f18_18_18734="Outcome of carotid endarterectomy by time of surgery";
var content_f18_18_18734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F70338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F70338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early carotid endarterectomy is associated with improved outcomes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Shown is the absolute reduction with surgery in the five-year cumulative risk of ipsilateral carotid ischemic stroke and any stroke or death within 30 days after carotid endarterectomy (CEA) in patients with 50 to 69 percent stenosis and &ge;70 percent stenosis without near occlusion stratified by the time from last symptomatic event to randomization. Numbers above the bars indicate actual absolute risk reduction. Vertical bars are 95 percent confidence intervals. These results suggest that CEA is likely to be of greatest benefit if performed within two weeks of the last neurologic event in patients with &ge;70 percent carotid stenosis. For patients with 50 to 69 percent stenosis, CEA may only have benefit if performed within two weeks of the last event.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rothwell PM, Eliasziw M, Gutnikov SA, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363:915.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18734=[""].join("\n");
var outline_f18_18_18734=null;
var title_f18_18_18735="Full mask ventilation";
var content_f18_18_18735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Full mask ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 158px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A full mask (covering the nose and mouth) as used to deliver nocturnal assisted ventilation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter C Gay, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_18_18735=[""].join("\n");
var outline_f18_18_18735=null;
